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GENERAL INTRODUCTION AND THESIS OUTLINE
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GENERAL INTRODUCTION
Colorectal cancer is a major contributor to cancer-related deaths 
worldwide1. In the Netherlands over 15,000 patients get diagnosed with 
colorectal cancer every year, three-fourth of these patients qualify for 
curative surgical treatment.2, 3 Treatment of colorectal cancer is shifting 
towards a patient-tailored approach and all patients should now be 
discussed in a multidisciplinary team.4 As the heterogeneity of patients 
and tumor characteristics increases, there is a growing need for timely 
and reliable information that measures the quality of treatment in these 
populations; so-called real world and real time information. 
Traditionally surgeons are concerned with measuring quality and 
outcomes of surgical interventions.5 As a result multiple changes have 
been made in the past regarding the surgical treatment of colorectal 
cancer with a measurable effect on patient outcomes. In rectal cancer 
surgery for instance, implementation and standardization of the 
total mesorectal excision (TME) technique using surgical training 
programmes has led to major improvements in local disease control and 
survival rates.6
Next to adjustments in surgical technique we are currently involved 
in optimization of colorectal cancer care by reorganizing the way 
healthcare is provided. Procedural volume for example has gained much 
attention in relation to outcomes of surgery, as hospital volume is seen 
as a proxy for surgical experience and the expertise of the involved 
multidisciplinary team.7 The Dutch Society of Surgery responded with 
an obligatory volume of at least 20 resections for rectal cancer per 
year per hospital, thereby stimulating centralisation of this procedure. 
Furthermore there is a development towards subspecialisation of 
surgeons and healthcare workers in colorectal cancer care. Due to this 
specialisation healthcare professionals are focussed to stay up to date 
with the latest developments in the field and are more likely to rapidly 
implement innovative techniques and ideas. 
Outcomes research
Outcomes research is a type of public health research, which studies 
variation in end results (outcomes) of different providers and the 
differences in (infra)structure and care processes leading to better or 
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worse outcomes. It applies to clinical and population based research 
that studies and seeks to optimize the end results of healthcare in terms 
of benefits to the patient and society. 
“Do no harm” is an important aim in medicine; all care provided 
should have a beneficial effect on a patient’s well-being.8 Healthcare 
is therefore captured in evidence-based guidelines, which dictate 
conditions for optimal care and form an important aspect of quality 
assurance. In the Netherlands the evidence-based guidelines on 
colorectal cancer surgery are developed by a multidisciplinary board 
and periodically revised.9 
For a long time it was not exactly known to which extent hospitals 
followed these guidelines and if this lead to variation in outcomes 
between providers. As a result the Dutch Surgical Colorectal Audit 
(DSCA) was founded in 2009, a national audit that is developed and 
managed by colorectal surgeons and gets its input through a web-based 
system.10 The DSCA provides risk-adjusted benchmarked feedback 
evaluating quality of care on a hospital level and compares hospitals 
with their peers. It gives medical teams information about their 
performance and stimulates processes that need to be developed or 
improved.11 Furthermore the DSCA identifies hospital variation in the 
Netherlands on a structure – process and outcome level. Studying this 
hospital variation provides us with valuable information that can be 
used to improve healthcare.12 
For instance data from the DSCA show that outcomes after colorectal 
cancer surgery have improved significantly since the start of the audit. 
There has been a significant reduction in postoperative morbidity and 
mortality for colorectal cancer patients as well as a reduced duration 
of postoperative admission time.10, 13 Moreover as a result of clinical 
auditing variation in guideline compliance between hospitals reduced, 
which had a measurable effect on quality of care (chapter 4). Clinical 
audits include large numbers of patients and contain patients with a 
high risk for unfavourable outcomes due to the absence of exclusion 
criteria, which are normally encountered in randomized controlled 
trials (RCT’s).14 Due to these characteristics, clinical audits are rich 
databases that provide a unique source of real-time, real-world data and 
could complement the information from RCT’s. 
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This thesis will describe different areas of medical research for which 
clinical audit data is used and will furthermore discuss the inherent 
statistical problems encountered in population studies. 
THESIS OUTLINE
Part I: Risk-adjustment in clinical auditing
Valid comparisons between hospital outcomes are essential for the 
audit, especially when these outcomes become transparent to the  
public, healthcare insurers and healthcare authorities. The 
heterogeneity of patients and tumors affects hospital outcomes. In 
oncology there is a trend towards centralisation of specific patient 
subgroups based on the rarity and complexity of their disease. To 
analyse the effect of this centralisation on casemix correction for 
outcome comparisons, the first part of this thesis studies differences 
in the effect of variables in the currently used casemix model between 
referral and non-referral hospitals. 
Part II: Quality improvement in the Dutch colorectal cancer care
The second part of this thesis focuses on quality improvement in 
Dutch colorectal cancer care.  Chapter 3 shows how the audit is used 
to monitor a quality improving initiative. As mentioned before the ASN 
implemented a compulsory minimal volume standard for rectal cancer 
surgery per hospital. This study describes the influence of hospital 
volume on circumferential resection margin (CRM) involvement - 
the most significant prognostic factor for local recurrence, distant 
metastasis and survival - after rectal cancer surgery. 
Chapter 4 evaluates the rates of CRM reporting by Dutch hospitals and 
CRM involvement after the implementation of the DSCA. Chapter 5 
identifies changes in the use of preoperative radiotherapy for  
rectal cancer in the Netherlands after the revision of the national 
colorectal cancer guideline. This guideline revision was stimulated by 




Part III: Data from clinical audits as a supplement to RCT’s
The third part of this thesis shows the complementary function of the 
clinical audit in providing data for clinically relevant research. 
Chapter 6 analyses the rate of postoperative morbidity and mortality 
after open versus laparoscopic surgery for colorectal cancer in specific 
subgroups of patients, including patients with a high preoperative 
risk for adverse outcomes. This chapter shows a possible method to 
deal with the inherent statistical problems that accompany population 
studies. 
Chapter 7 displays the quality of laparoscopic rectal cancer surgery 
in the Netherlands at present by comparing the data from the DSCA 
to the COLOR II trial. We performed a matched cohort study and show 
postoperative results after laparoscopic rectal cancer surgery a decade 
from start of the COLOR II trial. 
Chapter 8 shows the outcomes of patients with locally advanced colon 
cancer in the Netherlands, a population that is underreported in 
literature. The clinical audit provides important information on the 
quality and outcomes of their care.
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DIFFERENCES IN EFFECT OF CASEMIX VARIABLES 
BETWEEN REFERRAL AND NON-REFERRAL HOSPITALS 
IN THE NETHERLANDS AND RELEVANCE FOR HOSPITAL 
COMPARISONS.
Lieke Gietelink, Perla J. Marang – van de Mheen, Claudia Fischer, 





Background: Hospital comparisons based on outcome need to be 
adjusted for casemix. As there is a trend towards centralisation in 
oncology, patient population in specialized hospitals might differ 
from other hospitals to such an extent that the impact of casemix 
variables may be different for referral hospitals thereby affecting fair 
hospital comparisons. In addition, referral hospitals treat patients with 
paradoxical risk profiles e.g. young patients with advanced disease 
not adequately captured if no interactions are added. Therefore, our 
aim was to analyse whether the effect of variables used in the Dutch 
ColoRectal Audit (DCRA) casemix model are different between the 
referral and non-referral hospital population. Furthermore we added 
clinically relevant interactions to the standard model and evaluated 
their effect and added value on model performance. 
Methods: Patients who underwent a surgical resection for colon cancer 
between 2009 and 2015 (n=39,604) were selected from the DCRA. 10 
hospitals function as tertiary referral hospitals in the Netherlands and 
were selected as ‘referral hospitals’. We analysed differences in effect of 
variables between referral versus non-referral hospitals in the currently 
used multivariate regression model for postoperative complicated 
course and tested the added value of added interactions between age 
and Charlson comorbidity index, pT4 tumor and metastatic disease 
(M1). Model performance was assessed by a C-statistic based on an  
ROC curve.  
Results: Mean age of patients treated in referral hospitals is 3 years 
lower (p<0.001) than in non-referral hospitals. Patients treated 
in referral hospitals more often have pT4 disease or a Charlson 
comorbidity index of 2+ (p<0.001). The variables age, ASA score, tumor 
location, M1 disease, preoperative tumor complications, additional 
resection due to local tumor invasion or metastasis and pT classification 
have a significantly different effect (all p≤0.001) on postoperative 
complicated course in referral hospitals. Added interactions had no 
significant effect on outcomes for the referral population. A separate 
model for referral hospitals showed the best model fit. 
19
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Conclusion: This study shows that referral hospitals treat a different 
patient population and that the effect of variables on postoperative 
complicated course is different in the casemix model. A specifically 
fitted casemix model to the referral population shows best model 
performance for referral hospitals. 
20
INTRODUCTION  
Patient populations treated for a specific condition significantly differ 
across hospitals.1 Because patient and disease characteristics affect 
outcome, casemix is a confounder in between-hospital comparisons 
based on outcome. Therefore, casemix adjustment needs to be 
applied when comparing outcomes across hospitals with the aim to 
judge quality of hospital care. The most efficient way to execute risk 
adjustment is with a logistic regression model - in case of a binary 
outcome - that contains the most important predictors of the outcome 
parameter. 
In oncology, there is a trend towards centralisation of treatment of 
specific patient subgroups particularly in case of rare disease or high 
complexity of treatment.1, 2 Although colorectal cancer is one of the 
cancers with the highest incidence worldwide, specific patient groups 
with advanced stage of disease may benefit from treatment and thus 
cluster in expert centres. The patient population in such specialized 
hospitals might differ from the other hospitals to such an extent that the 
impact of different casemix variables (and thus also risk adjustment) 
may be different for referral hospitals.1, 2 
The models for casemix adjustment in the DCRA are implicitly weighted 
more due to the majority of high volume non-specialised care hospitals, 
with a smaller contribution of the few referral hospitals. Furthermore, 
the models only contain main effects for casemix adjustment, and no 
interaction terms. In this way, the assumption is made that there are no 
interactions between the variables (e.g. comorbidities have the same 
effect on outcome across all ages), and it is uncertain whether these 
assumptions are actually met, especially in the case of paradoxical 
risk profiles – i.e. young patients with advanced disease - in some 
(referral) hospitals. Therefore, our aim was to analyse whether the 
effect of variables used in the DCRA casemix model is different within 
the referral versus non-referral hospital population and to evaluate the 






Data were derived from the DCRA, a disease specific national audit.3 
This audit collects information on patient, tumor and treatment 
characteristics of all patients undergoing a resection for primary 
colorectal cancer in the Netherlands and their postoperative outcomes. 
All Dutch hospitals participate, with approximately 97 percent 
completeness in 2012 based on comparison with the Netherlands 
Cancer Registry (NCR). Details of the DCRA regarding data collection 
and methodology have been published previously.1, 3, 4 All patients 
with colon cancer registered from 1st of January 2009 until the 1st of 
September 2015 were included in this study. For the clarity of this study 
we excluded patients with rectal cancer, due to the different variables 
that influence postoperative outcomes in these two populations.3 
Hospitals
In the Dutch healthcare system, there are 8 university hospitals and 
2 non-university hospitals that function as tertiary referral hospitals 
for high-complex colorectal cancer care and therefore treat a selected 
patient group, of the total of 92 hospitals. These hospitals will be named 
‘referral hospitals’ throughout the continuation of this manuscript. The 
population of all referral hospitals combined is referred to as “referral 
population”, the population of all non-referral hospitals combined is 
referred to as “non-referral population”. 
Outcome Measures
We used the short-term postoperative outcome of complicated 
postoperative course for our analyses. Complicated postoperative 
course was defined as any complication leading to a reintervention 
(radiological/surgical), prolonged hospital stay (>14 days) or death, 
within 30 days from surgery.1, 4-6 
Casemix correction model and interactions
Standard casemix correction model 
We used the standard casemix correction model for colon cancer 
as currently used in the DCRA as reference model.7 In short, this 
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multivariate regression model for outcomes after a resection for 
colon cancer includes several patient and tumor characteristics: age, 
gender, American Society of Anaesthesiologists (ASA) score, Charlson 
comorbidity index, Body Mass Index (BMI), tumor location, metastatic 
disease (M1), preoperative tumor complications, emergency surgery, 
additional resection due to local tumor invasion or metastasis and TNM 
classification (pT and c/pM classification). The 5th edition of the TNM 
classification is reported in the DCRA. 
Interactions
Clinically relevant interactions were derived from expert opinion. 
Interactions between the variables age and Charlson comorbidity index, 
age and pT4 tumor, and age and metastatic disease were considered as 
potentially different in the referral versus non-referral population and 
therefore used in our analysis. 
Statistical analysis
We first calculated differences between the referral and non-referral 
population for all variables included in the DCRA casemix model. 
Differences in casemix between patients treated in referral versus non-
referral hospitals were tested using chi-square tests for categorical 
variables and t-tests for continuous variables. Hospital outcomes 
adjusted for casemix on postoperative complicated course per hospital 
in 2013-2014 were presented in a funnel plot using the standard 
casemix model, showing the overall average outcome with its 95% 
confidence limits, based on a Poisson distribution, varying in relation to 
the population size and indicating referral versus non-referral hospitals. 
Then we estimated a casemix model separately for referral hospitals and 
non-referral hospitals, by including the same casemix variables as above 
in the model but only selecting the referral or non-referral population. 
In this way we show whether casemix variables have different effects 
on the outcome of postoperative complicated course in referral versus 
non-referral hospitals. In order to test whether casemix variables have 
a significantly different effect in the referral population compared to 
the non-referral population we added an interaction of each variable 
with the variable “referral hospital (yes/no) to the standard model. A 
significant interaction in this analysis indicates a significantly different 
23
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effect of the variable on the outcome of postoperative complicated 
course in the referral versus non-referral hospitals. To test the added 
value of interactions we extended the standard casemix model (for 
the total, non-referral and referral population) for the outcome of 
postoperative complicated course with clinically relevant interactions.
Model performance was assessed using a C-statistic based on a 
Receiving Operator Characteristic Curve (ROC curve), both for the 
standard model and for the models fitted for referral and non-
referral hospitals separately and with or without clinically relevant 
interactions for the outcome of postoperative complicated course. We 
also analysed the model performance of the standard casemix model 
applied to referral hospitals; by saving the predicted values of the 
standard casemix model for the referral population and then calculate a 
c-statistic as above. 
Statistical analyses were carried out with the statistical software 
packages SPSS version 18.0 (SPSS, Chicago, IL, USA). A p-value of 0.05 
was considered significant in all analyses.
RESULTS
Patients and hospitals
Table 1 shows the percentages of patient and tumor characteristics 
for referral and non-referral hospitals. Referral hospitals more often 
treat younger patients and more often patients with comorbidity and 
advanced disease (i.e. pT4 tumor and metastasis). However, there is 
variance in patient characteristics among the referral hospitals, e.g. 
mean age for colon cancer varies from 62.8 to 71.2 years per hospital 
and the percentage of patients with a pT4 colon tumor from 13.0 to 
26.0% (data not shown).
Figure 1 shows a funnel plot with the adjusted percentage of 
postoperative complicated course for colon cancer per hospital in 2013-
2014, using the standard casemix model. None of the referral hospitals 
had significantly worse results compared to the other Dutch hospitals. 
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Casemix correction model and interactions
Table 2a shows the effect of the different casemix variables on 
postoperative complicated course after colon cancer resections fitted 
to respectively the total (general), non-referral and referral population. 
Overall, the estimated effects in the general model show most 
resemblance to the non-referral population (descriptive). The variables 
age, ASA score, tumor location, metastatic disease, preoperative tumor 
complications, additional resection due to local tumor invasion or 
metastasis and pT classification have a significantly different effect (all 
p≤0.001) on the outcome postoperative complicated course in referral 
hospitals compared to non-referral hospitals. 
In table 2b the clinically relevant interactions are added to the 
casemix correction models for postoperative complicated course. The 
interaction effect of age with Charlson score and age with T4 tumor 
are significant in the total and non-referral population. None of these 
interactions were significant in the referral population. In the non-
referral population, the age-T4 interaction and age-Charlson interaction 
were significantly associated with postoperative complication outcome. 
By adding the interactions, T4 was no longer independently associated 
with postoperative complications, whereas the independent effect of 
age remained. So T4 is only a significant predictor of the outcome in 
combination with age. The same was true for the interaction of age with 
Charlson comorbidity index. 
Table 3 shows the C-statistic for each casemix correction model. The 
addition of interaction terms did not improve model performance. 
However, a separate model for referral hospitals showed better model 
fit for referral hospitals than the standard casemix correction model 
applied to referral hospitals (with saved predicted values) (C-statistic 
of 0.707 rather than 0.688 for postoperative complicated course). A 
separate model for non-referral hospitals did not improve model fit 
for non-referral hospitals compared with the standard model applied 
to non-referral hospitals (C-statistic of 0.674 for postoperative 




The present study has shown that multiple casemix variables have 
a different effect on postoperative complicated course in referral 
hospitals than in non-referral hospitals. The currently used casemix 
model (general model) that is fitted in the total population performes 
equally well in the non-referral population as a casemix model 
specifically fitted in non-referral hospitals only. In contrast, the general 
model performes worse in the referral population when compared to 
a model specifically fitted in referral hospitals only. As hypothesized, 
casemix correction models based on the total population showed most 
resemblance to the non-referral population. However, the interactions 
that were added to the model were only significantly associated with the 
postoperative complication outcome in the non-referral population but 
not in the referral population. None of the added interactions resulted 
in better model performance. 
The DRCA provides risk-adjusted benchmarks as feedback to evaluate 
hospital quality of care by comparing hospitals with their peers. It gives 
surgeons information about their performance and aims to thereby 
stimulate processes that need to be developed or improved.8 In order 
to have the intended effect, healthcare providers need to trust their 
feedback and casemix correction should therefore be as adequate 
as possible. As this paper shows, referral hospitals seem to treat a 
different patient population. If casemix variables (e.g. age) would 
have the same effect on the outcome in both referral and non-referral 
hospitals, but only the distribution would differ (e.g. have more young 
patients), then performing casemix adjustment in one model will be 
adequate. However, if the effect of casemix variables differs as shown 
in this study, then casemix adjustment is likely to be inadequate and 
particularly in referral hospitals as the effect in the total model closely 
resembled that in the non-referral population. In addition, important 
information determining the caseload of this patient population may 
be lacking, i.e. detailed information about previous surgery, index 
surgery, intra-abdominal adhesions, multimodality treatments, and 
medication use (e.g. steroids) and thus cannot be taken into account 
in hospital comparisons. The addition of such variables would lead 
to fairer comparison but would increase the registration burden and 
these variables are often difficult to register unambiguously. A separate 
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model for referral centres might solve the before mentioned problem 
by creating a comparison with similar hospitals (‘hospitals like mine’) 
but might induce new questions.  That is whether we are sure that any 
difference in average performance between these 2 groups of hospitals 
is based on the complexity of patients and not on a difference in quality 
of care and whether a hospital treats sufficient referral patients to be 
classified as a referral hospital. 
In 2015 Walker at al. published a paper on casemix correction models 
in the field of hospital comparisons.9 On the basis of previous literature 
they concluded that most publications described suboptimal methods 
for casemix model development, i.e by the usage of significance testing 
for the selection of risk factors, a small sample size, categorizing 
continuous risk factors and ignoring potential interactions between risk 
factors. They then developted a casemix correction model with casemix 
variables that were selected on clinical grounds and complemented 
the model with interaction terms. The only stable interaction - with a 
bootstrap method - was the interaction between age and metastases 
and was added to the casemix correction model. In our study we added 
interactions based on clinical relevance in accordance with the selection 
of the risk factors in the casemix correction model, but only age-T4 and 
age-comorbidity were found to be significantly associated and only in 
non-referral hospitals. Given that model fit also did not improve, it is 
not clear whether adding these interactions will be of added value for 
our hospital comparisons.
Our study has some limitations. The division into referral and non-
referral hospitals was based on expert consensus. Over time, hospitals 
may be in one or the other group e.g. if hospitals merge with other 
hospitals. Furthermore it remains unclear whether referral hospitals 
have been insufficiently adjusted with the current casemix model, 
as the effect of some variables was higher in the referral population 
than in the general model but also lower for other variables so that 
the net effect remains unclear. Within the general model, none of the 
referral hospitals performed significantly worse compared to other 
hospitals on postoperative complicated course in the years 2013-2014. 
Nevertheless this study clarifies that some variables have a different 
effect on postoperative outcome in the referral population, and model 
performance does improve when the casemixmodel is specifically fitted 
to the referral population. 
27
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In conclusion, this study showed that referral hospitals treat a different 
population in which the effect of casemix variables on postoperative 
complicated course is different after a resection for colon cancer. Adding 
clinically relevant interactions did not improve model performance in 
referral hospitals as these were not signficantly associated with the 
outcome. A casemix model which was specifically fitted to the referral 
population showed the best model performance for  
referral hospitals. 
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Table 1. Patient and tumor characteristics of colon cancer patients in 
referral hospitals and non-referral hospitals.  
 Non-referral Referral   
 N % N % P-value
Total 36284  3320   
Age <= 60 5780 15.9 768 23.1 <0.001
Age (mean) 71  68  <0.001
Charlson 2+ 9252 25.5 1069 32.2 <0.001
pT4 5920 16.4 683 20.8 <0.001





















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Table 3: Model performance of casemix correction models for postoperative 
complicated course calculated for the total, non-referral and referral 
population estimated by separate models per population with or without 
added interactions and estimated per population with saved predicted 
values. 
 Colon Postoperative complicated course 
  C-statistic
No interactions Total 0.675
 Non- referral 0.674
 Referral 0.707
   
With interactions Total 0.675
 Non- referral 0.674
 Referral 0.707






Figure 1: Funnel plot showing differences in risk-adjusted percentages of 
postoperative complicated course after resection for colon cancer between 
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CIRCUMFERENTIAL RESECTION MARGIN INVOLVEMENT: 
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ABSTRACT
Objective: To evaluate the association between hospital volume and 
CRM involvement in rectal cancer surgery.
Summary Background Data: To guarantee the quality of surgical 
treatment of rectal cancer, the Association of Surgeons of the 
Netherlands (ASN) has stated a minimal annual volume standard of 
20 procedures per hospital. The influence of hospital volume has been 
examined for different outcome variables in rectal cancer surgery. Its 
influence on the pathological outcome (CRM) however remains unclear. 
As long-term outcomes are best predicted by the CRM status, this 
parameter is of essential importance in the debate on the justification of 
minimal volume standards in rectal cancer surgery. 
Methods: Data from the Dutch Surgical Colorectal Audit (2012) was 
used. Hospital volume was divided into three groups and baseline 
characteristics were described. The influence of hospital volume on CRM 
involvement was analysed, in a multivariate model, between low and 
high volume hospitals, according to the minimal volume standards. 
Results: This study included 5161 patients. CRM was recorded in 86 
percent of patients. CRM involvement was 11 percent in low volume 
group versus 7,7 and 7,9 percent in the medium and high volume group 
(p=<0.001). After adjustment for relevant confounders, the influence of 
hospital volume on CRM involvement was still significant (OR 1.54; 95% 
CI 1,12-2,11).
Conclusions: The outcomes of this pooled analysis support minimal 
volume standards in rectal cancer surgery. Low hospital volume was 
independently associated with a higher risk of CRM involvement (OR 




Improving the outcomes of oncologic surgery has been widely discussed 
over the last decades.1 In this context, hospital differences regarding 
quality of care have received much attention in recent years.2
In rectal cancer surgery, implementation and standardization of the 
technique of total mesorectal excision (TME) using surgical training 
programmes, as well as the introduction of preoperative (chemo) 
radiotherapy has led to major improvements in local disease control 
and survival rates.3-5 Despite this evolution, a lower though significant 
proportion of these patients will develop local recurrences.6, 7 The status 
of the circumferential resection margin (CRM) is a significant prognostic 
factor for local recurrence and distant metastasis and the most accurate 
predictor of survival after rectal cancer surgery.7-10 
Several patient, tumor and treatment related factors have been 
associated with a higher risk of CRM involvement, such as tumor 
stage, response to neo-adjuvant radiotherapy and abdominoperineal 
excision (APR).7, 11 Consequently, hospital variation in outcomes may 
be influenced by differences in patient- and tumor related factors.2 
Hospital characteristics, like procedural volume, have also proven to be 
important factors influencing outcomes in oncologic surgery, including 
rectal cancer treatment.12-14 Hospital volume seems to be a proxy for the 
experience of the multidisciplinary team (MDT) and more specifically the 
surgical quality with respect to a specific procedure. 
In the Netherlands a standard was set at 20 resections for rectal cancer 
per hospital per year. The relation between hospital volume and specific 
pathological outcome measures, such as CRM involvement, is less well 
defined with contradictory findings in literature.15-18  Therefore, the 
objective of this study was to evaluate the effect of hospital volume on 
CRM involvement in rectal cancer surgery in the Netherlands, based on 
data from a national clinical registry.
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METHODS 
Data were derived from the Dutch Surgical Colorectal Audit (DSCA), 
a disease specific national audit.19 This audit collects information on 
patient, tumor, treatment and outcome characteristics and contains 
approximately 97 percent of all patients with a resection for primary 
colorectal carcinoma in the Netherlands in 2012. The dataset is based 
on evidence-based guidelines and compared on a yearly basis with 
the data registered in the Netherlands Cancer Registry (NCR).20 The 
registered CRM rate in the DSCA was 80 percent in 2011 and 92 percent 
in 2012 with a high level of concordance with the NCR. Details of this 
dataset regarding data collection and methodology have been published 
previously.2, 19 
Patients
For this study, no ethical approval or informed consent was required 
under Dutch law. All patients (n=5552) undergoing surgical resection 
for primary rectal cancer between January 1st 2011 and December 
31th, 2012, and registered in the DSCA before March 15, 2013, were 
evaluated. Minimal data requirements to consider a patient eligible for 
analyses were information on tumor location, date of surgery and 30-
day mortality (n=5534). All these patients, except those treated with a 
transanal resection (n=140), were included for the calculation of annual 
hospital volume. However, to create a homogenous cohort, patients with 
multiple synchronous colorectal tumors (n=233) were excluded from 
the analysis.
CRM involvement
CRM was considered positive if tumor cells were in a distance of 
≤1mm from the inked margin according to the definition of the Royal 
college of Pathologists. CRM involvement was only calculated for 
patients with a recorded CRM. The percentage of CRM involvement per 
hospital was presented in a funnel plot, showing the overall average 
CRM involvement with its 95% confidence limits, based on a Poisson 
distribution, varying in relation to the population size. The plot allowed 
for identification of hospitals with a CRM involvement rate that was 




The mean annual operative caseload was calculated for each hospital based on 
their respective numbers of rectal cancer cases, including patients with multiple 
synchronous colorectal tumors. Volume was stratified in two groups (< 20 and ≥ 
20 cases/year), based on the mandatory annual volume of rectal cancer surgery 
per hospital in the Netherlands and three groups (< 20, 20-40, ≥ 40 cases/year) 
to evaluate the influence of a higher hospital volume than is currently required. 
Patients with an unknown CRM status were not excluded from this calculation. 
Potential patient- and tumor specific risk factors (casemix) for CRM involvement 
were selected from the dataset and, together with treatment characteristics, 
compared between the three volume groups using the chi-square test. 
Subsequently, a univariable analysis was performed to determine the effect of 
hospital volume on CRM involvement. The significance level was set at a two-
tailed p-value of 0.05. Factors were entered in the multivariable analysis at a 
p-value of 0.10 using an ENTER model. No process or treatment characteristics 
were included in the multivariable analysis for adjustment. 




A total of 5,161 patients, registered by 91 hospitals, met the inclusion criteria. 
Hospitals were categorized into three volume groups; low volume (n=25), 
medium volume (n=47) and high volume hospitals (n=19). Patient, tumor, 
treatment and outcome characteristics were displayed by hospital volume 
category in table 1. In medium and high volume hospitals, there was a higher 
proportions of advanced tumors (cT3-4: 68 and 66 versus 59%, p=< 0.001) and 
elective surgery (1,8 and 1,1 versus 3,7%). There was an uneven distribution 
in preoperative pelvic imaging; high volume hospitals showed a significantly 
higher percentage of patients with no recorded type of imaging. (7.0 versus 
3.1 and 2.1%, p=< 0.001). Significant differences in type of neo-adjuvant 
treatment were observed between hospital categories with increasing use of 
chemoradiotherapy and decreasing use of short course radiotherapy (SCRT) 
with increasing volume. As for the type of surgical procedure, there was no 
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difference in APR rate, but medium volume hospitals treated more 
patients by laparoscopy than the other volume categories did (58 versus 
50 and 40%, p=<0.001). Medium and high volume hospitals showed a 
higher percentage of patients with more than 10 examined lymph nodes. 
There was no significant difference between these groups for sex, age, 
ASA classification, Body Mass Index, distance from the tumor to the anal 
verge, registered CRM and postoperative morbidity and mortality. 
CRM involvement
CRM was recorded in 86 percent of all included patients, with no 
marked differences between the volume categories. Univariable analysis 
showed 8 factors with a significant influence on CRM involvement 
(table 2). The significance level was set at a two-tailed p-value of 0.10. 
Sex, non-elective surgery, distance between tumor and the anal verge, 
a preoperative MRI, clinical T classification, preoperative (chemo) 
radiotherapy, laparoscopic surgery and the APR procedure were of 
significant influence. 
Hospital volume significantly influenced the rate of CRM involvement. A 
positive CRM was more frequently encountered in low volume hospitals 
compared to medium and high volume hospitals (p=0.026). However, 
no difference was seen between medium and high volume hospitals (OR 
0.69 and 0.71). When CRM rate was analysed using a cut-off level of 20 
procedures per year, hospitals with high volume had significantly lower 
rates of CRM involvement than hospitals treating <20 patients annually 
(OR 0.70, CI 0.52 - 0.94).  
Forrest plot
The influence of hospital volume (low volume vs medium/high volume) 
on CRM involvement in specific subgroups was plotted in a forest plot 
(figure 1). This figure shows that there is a marked influence of hospital 
volume in certain subgroups of patients. Low hospital volume has, like 
was already apparent in the whole group, in most groups a negative 
effect on CRM involvement, as is shown by the different odds ratio’s. 
Multivariable analysis 
With adjustment for sex, clinical T classification and the distance from 
the tumor to the anal verge, hospital volume was still of significant 
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influence on CRM involvement (table 3). The risk of CRM involvement 
was 1.5 times as high in patients operated in a low volume setting 
(OR 1.54, CI 1.12-2.11). Furthermore, clinical T classification was an 
independent predictor for CRM involvement (cT3; OR 1.31, CI 1.00-1.72, 
cT4; OR 2.99, 2.08-4.31 when compared to cT1-2). 
Funnelplot
Figure 2 shows the CRM involvement rate, after adjustment for casemix, 
of 91 hospitals varying between 0 and 50 percent. All hospitals, except 
for 3, were within the upper 95 percent confidence limit of the average. 
Nine hospitals showed significantly lower rates than average. 
DISCUSSION
This population-based study is the first to analyse and demonstrate 
a casemix adjusted association between hospital volume and CRM 
involvement in rectal cancer resections. The relation remained 
significant after adjustment for clinical T classification, distance from 
the tumor to the anal verge and whether or not the resection took place 
in an elective setting. Patients treated in low-volume hospitals had a 
1.5-fold higher risk of CRM involvement than patients operated in high-
volume hospitals. Treatment strategy related factors that were both 
inherently related to hospital preferences or experience as well as to 
outcome (e.g. preoperative (chemo) radiotherapy, preoperative MRI, 
surgical procedure and approach) were not adjusted for. 
Many studies have evaluated the influence of procedural volume on 
clinical outcomes like morbidity, mortality and survival.12-14 Only few 
studies evaluated the influence of this factor on oncological outcome 
parameters like CRM.15-18 Supportive evidence for the influence of 
hospital volume on CRM involvement has been scarce. Harling et al. 
included over 5,000 patients and found no influence in univariable 
analysis of hospital volume on pathological outcome.17 Another smaller 
(n=302) more recently published study by Kennely et al. showed no 
relationship either by analysing the influence of unit APR volume (≤5, 
>5 per year) on CRM involvement.18 Cornish et al. included over 7,000 
patients and did find a significant relationship in univariable analysis. 
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High volume trusts (annual volume ≥190 colorectal procedures, rectal 
procedures were not mentioned) were more likely to have a negative 
CRM than trusts with a lower volume of cases. They did not investigate 
this relationship in a multivariable analysis. A higher volume per 
surgeon was not associated with improved CRM rates.16 Borowski 
et al analysed the influence of both hospital and surgeon volume on 
CRM involvement; high volume surgeons had better outcomes, though 
hospital volume was not associated with this outcome.15 
The definition of a high volume hospital differs between countries; 
minimal volume standards seem to be introduced on a rather arbitrary 
basis.15 Numbers required to qualify a hospital as ‘high volume’ varied 
widely between studies. Cut off points for low volume hospitals ranged 
between 5 and 20 and for high volume hospitals between 10 and 40 
cases a year.21 National audits like the DSCA make continuous verification 
of these volume standards possible, which is important as it has 
substantial implications for healthcare delivery. Extensive population 
based audit registrations with feedback adjusted for casemix would be 
the ideal alternative and could make rigid minimal volume standards 
obsolete. However, until this is fully realised, minimal volume standards 
can result in better care for patients with colorectal cancer.14, 22   
Our study has some limitations. As it is known from other national 
audits, the status of the CRM is not registered for every patient.23 
The proportion of reported CRM, however, did not differ significantly 
between the hospital volume groups. Eighty percent of the patients 
had a registered CRM in 2011, which increased to 92 percent in 2012. 
This is a high percentage compared to the audits in our neighbouring 
countries like the UK (60%) and Belgium (88%).23, 24 The rate of MRI 
documented threatened CRM (distance to the mesorectal fascia < 1 mm) 
was not registred for 71 percent of all patients. Therefore, this variable 
was excluded from analysis. The available data revealed that high 
volume hospitals treated more patients with a threatened CRM (8.2% 
versus 7.3%) and achieved higher percentages of a negative CRM in 
these patients (92% versus 78 %). This suggests that MRI documented 
threatened CRM would not significantly have changed outcomes.
Furthermore, as the level of expertise in high volume hospitals could 
lead to better patient selection, diagnostic procedures and therapeutic 
strategies, translating into better outcomes for patients, we did not 
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adjust for treatment strategy related factors such as a preoperative MRI and 
neoadjuvant treatment. Nevertheless, we explored the potential impact of the 
use of ‘pre-treatment MRI’ and ‘neoadjuvant treatment’ on CRM positivity. 
Inclusion of these two additional variables in the multivariable model resulted 
in a persisting, significant and independent effect of hospital volume on CRM 
positivity (OR 1,58; 95% CI 1,15 – 2,17). 
As the DSCA provides no results on long-term outcomes, we were only able 
to analyse CRM involvement as a surrogate endpoint. Nonetheless, it seems 
reasonable to extrapolate these outcomes to the overall quality of care for rectal 
cancer patient as the status of the CRM gives an accurate estimation of long-
term oncological outcomes.25
The influence of volume on the outcomes of rectal cancer surgery has been 
analysed for procedural volume per surgeon and per hospital.12, 15 The working 
mechanism has been described in great detail.26 A large volume per surgeon 
results in greater experience but on top of that it is generally believed that 
volume is to be seen as a ‘proxy’ for other important structural and process 
factors in the chain of multidisciplinary treatment.13, 22  This study underlines 
the importance of a high quality care process, extending beyond the surgical 
part of the treatment. The quality of these factors is more likely to be realised 
and sustained in high volume hospitals.27, 28 By this means, the Association 
of Surgeons of the Netherlands decided to dictate minimal volume standards 
per hospital instead of minimal annual volume standards per surgeon. It is 
important however to conclude that individual small volume hospitals can 
provide the same standard of care compared to high volume hospitals as shown 
in figure 2. In this way, hospital volume does not guarantee quality. 
In conclusion, this article supports the minimal annual volume standard of 20 
rectal cancer resections a year, implemented by the Association of Surgeons 
of the Netherlands, by showing an independent and significant relationship 
between volume and CRM involvement. The question is whether there is a need 
for further centralisation of rectal cancer surgery in the Netherlands, since 
there were no marked differences in CRM involvement rates between medium 
and high volume hospitals and CRM status alone may not be the only outcome 
measure to determine optimal volume.
Acknowledgment: The authors would like to thank all surgeons, registrars, 
physician assistants and administrative nurses that registered all the patients in 
the DSCA, as well as the Dutch Surgical Colorectal Audit group. 
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Table 1: Patient, tumor, treatment and outcome characteristics categorised 
per hospital volume. Complicated postoperative course: a complication 
leading to a surgical, endoscopic or radiological re-intervention, to an in-
hospital stay of more than 14 days, or to death. MDT=Multidisciplinary 
team meeting; SCRT=Short course radiotherapy; CRT=Chemoradiotherapy; 
LAR=Low anterior resection; APR=Abdominoperineal resection. 
 < 20 / year  20-40 / year  > 40 / year ӽ2
No. of patients 618 12% 2607 50% 1936 38%  
No. of hospitals 25  47  19   
Patient        
Sex       0.780
male 390 63% 1609 62% 1192 62%  
female 228 37% 998 38% 744 38%  
Age       0.751
<75 yrs 232 72% 993 73% 729 74%  
>75 yrs 91 28% 364 27% 257 26%  
ASA classification       0.500
I - II 519 84% 2141 82% 1603 83%  
III 90 15% 445 17% 320 17%  
IV - V 6 1.0% 15 0.6% 12 0.6%  
Body mass index       0.509
<20 8 1.7% 53 2.7% 44 3.2%  
20-25 155 34% 620 32% 427 31%  
25-29 207 45% 879 45% 655 47%  
>30 89 19% 393 20% 260 19%  
Tumor        
Clinical T classification       <0.001
cT 1-2 237 41% 810 32% 617 35%  
cT3 309 53% 1531 60% 965 54%  
cT4 35 6.0% 210 8.2% 205 12%  
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Distance tumor to anal 
verge
      0.112
<=5 cm 229 40% 900 36% 697 40%  
6-10 cm 230 40% 1035 42% 677 39%  
>10 cm 116 20% 558 22% 382 22%  
Diagnostics        
Preoperative MRI 
pelvis
      <0.001
No 41 6.6% 197 7.6% 127 6.6%  
Yes 558 90% 2356 90% 1674 87%  
Unknown 19 3.1% 54 2.1% 135 7.0%  
Preoperative MDT 
meeting
592 96% 2524 97% 1896 98% 0.009
Treatment        
Preoperative (chemo)
radiotherapy
      <0.001
None 88 14% 409 16% 412 21%  
SCRT 306 50% 1205 46% 743 38%  
CRT 224 36% 993 38% 781 40%  
Procedure       0.356
LAR 420 70% 1782 70% 1245 68%  
APR 182 30% 766 30% 587 32%  
Laparoscopic surgery 310 50% 1522 58% 763 40% <0.001
Non-elective surgery 23 3.7% 46 1.8% 22 1.1% <0.001
Pathology        
More than 10 harvested 
lymph nodes 412 67% 1885 72% 1394 72% 0.017
Registred circumferential 
resection margin 527 85% 2241 86% 1662 86% 0.907
Postoperative course        
Complicated 
postoperative course 167 27% 621 24% 436 23% 0.071
30-day mortality 19 3.1% 53 2.0% 43 2.2% 0.288
Continuation of Table 1
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Table 2: Prevalence of CRM involvement in various casemix factors and univariate 
analysis of the influence of these casemix factors on CRM involvement. CRM+ = 
CRM involvement, MDT = Multidisciplinary team, SCRT=Short course radiotherapy, 
CRT=Chemoradiotherapy, LAR=Low anterior resection; APR=Abdominoperineal 
resection.
 CRM + OR 95% CI 95% CI
Patient     
Sex
male 8.7% ref   
 female 7.2% 0.81 0.65 1.02
Age     
< 75 yrs 8.1% ref   
 > 75 yrs 7.4% 0.92 0.65 1.29
 ASA classification     
I - II 7.8% ref   
III 9.7% 1.26 0.95 1.66
IV - V 12% 1.60 0.48 5.39
 Body mass index     
<20 11% 1.21 0.61 2.42
20-25 9.3% ref   
25-29 8.0% 0.85 0.64 1.12
≥30 7.6% 0.80 0.56 1.14
Tumor     
Clinical T-classification
cT 1 and 2 6.4% ref   
cT3 7.8% 1.23 0.95 1.60
cT4 17% 2.91 2.06 4.11
Distance tumor to anal verge
≤ 5 cm 9.6% 1.17 0.87 1.56
6-10 cm 6.7% 0.80 0.59 1.09
> 10 cm 8.3% ref   
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Diagnostics     
Preoperative MRI pelvis
no 14% 1.84 1.29 2.62
yes 7.9% ref   
unknown 4.2% 0.51 0.22 1.16
Preoperative MDT meeting     
yes 10% 1.26 0.67 2.37
no 8.1% ref   
Treatment     
Preoperative (chemo)
radiotherapy
None 12% ref   
SCRT 5.7% 0.45 0.33 0.61
CRT 9.6% 0.80 0.60 1.06
Procedure
LAR 7.1% ref   
APR 10% 1.49 1.19 1.86
Approach
Open 9.8% ref   
Laparoscopic 6.5% 0.64 0.51 0.79
Setting
Elective 7.9% ref   
Urgent 24% 3.63 2.01 6.54
Hospital volume     
Volume in 2 groups
low volume 11% ref   
high volume 7.8% 0.697 0.517 0.939
Volume in 3 groups
low volume 11% ref   
medium volume 7.7% 0.69 0.50 0.94
high volume 7.9% 0.71 0.51 0.99
Continuation of Table 2
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Table 3: Assessment of the influence of hospital volume on CRM involvement in a 
multivariate analysis. CI=Confidence interval; OR=Odds ratio. 
 Sig. OR 95% CI 95% CI
Sex
Male    ref
Female .112 0.82 0.65 1.05
Clinical T classification
cT 1 and 2    ref
cT3 .050 1.31 1.00 1.72
cT4 .000 2.99 2.08 4.31
Distance tumor - anal verge
≤ 5 cm .654 1.07 0.79 1.45
6-10 cm .230 0.83 0.60 1.13
> 10 cm    ref
Hospital volume
low volume .008 1.54 1.12 2.11
high volume    ref
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Figure 1: Forest plot representing the OR and CI of the influence of low 
hospital volume versus high hospital volume on CRM involvement, seperately 
presented for different subgroups (hier subgroepen beschrijven?) cT=clinical 
T classification, cN=clinical N classification, LAR=Low anterior resection, 




Figure 2: Funnel plot showing differences in risk-adjusted CRM involvement 
rates between hospitals (2011-2012). Casemix adjustments were made for sex, 
clinical T classification and the distance from tumor to the anal verge.
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REDUCED CIRCUMFERENTIAL RESECTION MARGIN 
INVOLVEMENT IN RECTAL CANCER SURGERY; RESULTS OF 
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ABSTRACT
Background: The circumferential resection margin (CRM) is a 
significant prognostic factor for local recurrence, distant metastasis 
and survival after rectal cancer surgery. Therefore, availability of this 
parameter is essential. Although the Dutch TME trial raised awareness 
about CRM in the late 1990s, quality assurance on pathologic reporting 
was not available until the Dutch Surgical Colorectal Audit (DSCA) 
started in 2009. This study describes the rates of CRM reporting and 
CRM involvement since the start of the DSCA and analyses whether 
improvement of these parameters can be attributed to the audit. 
Methods: Data of the DSCA (2009 - 2013) was analysed. Reporting 
of CRM and CRM involvement was plotted for successive years and 
variation of these parameters were analysed in a funnelplot. Predictors 
of CRM involvement were determined in univariable analysis and the 
independent influence of year of registration on CRM involvement was 
analysed in multivariable analysis. 
Results: A total of 12,669 patients were included for analysis. The 
mean percentage of patients with a reported CRM increased from 52.7 
to 94.2 percent (2009-2013) and interhospital variation decreased. 
The percentage of patients with CRM involvement decreased from 14.2 
to 5.6 percent. In multivariable analysis, the year of DSCA registration 
remained a significant predictor of CRM involvement.
Conclusion: After the introduction of the DSCA, there has been a 
dramatic improvement in CRM reporting and a major decrease of CRM 
involvement after rectal cancer surgery. This study suggests that a 





Surgical resection remains the cornerstone of curative treatment 
in rectal cancer.(1) The implementation and standardization of the 
total mesorectal excision technique (TME) and the introduction of 
preoperative (chemo) radiotherapy have led to improved oncological 
outcomes.(2, 3) The circumferential resection margin (CRM) indicates 
the distance from the tumor to the resection plane in a transverse 
section through the TME specimen. Tumour negative, non-involved, 
CRM is defined as the absence of microscopic tumor cells within 1 mm 
of the inked resection margin, This is the most significant prognostic 
factor for local recurrence, distant metastasis and survival after rectal 
cancer surgery.(4) Therefore this parameter provides both important 
information on the quality of surgical resection and on the prognosis of 
the patient. 
Because of its prognostic value, the CRM has been frequently used as a 
surrogate endpoint in randomised controlled trials (RCT’s).(5,6) In the 
Netherlands, a standard pathology protocol to examine a TME specimen 
was introduced in the 1990s related to the start of the Dutch TME trial.
(5) Due to this standardization, 97 percent of patients included in this 
trial had a reported CRM.(2) In subsequent years, until the start of the 
Dutch Surgical Colorectal Audit (DSCA) in 2009, there was no national 
quality assurance on histopathological reporting and the CRM was 
presumably less frequently reported in routine practice outside a  
trial setting.  
The DSCA evaluates and reports on the quality of care of primary 
colorectal cancer surgery.(7) It provides periodic feedback to all 
hospitals in the Netherlands on a set of quality measures,  
including two indicators regarding the CRM in rectal cancer surgery. The 
objective of this study was to evaluate the rates of  
CRM reporting and CRM involvement throughout the successive years 
of the DSCA registration. Secondly, it analyses changes in these CRM 
related quality indicators over time and investigates the potential 
contribution of the DSCA to observed changes in a multivariable model. 
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METHODS 
Data were derived from the DSCA, a disease specific national audit. This 
audit collects information on patient, tumor, treatment and outcome 
characteristics and containes data on approximately 97 percent of all 
patients who underwent a resection for primary colorectal carcinoma 
in the Netherlands.(8) The dataset is based on evidence-based 
guidelines and compared on a yearly basis with the data registered in 
the Netherlands Cancer Registry (NCR). Details of this dataset regarding 
data collection and methodology have been published previously.(7,9) 
Patients
For this study, no ethical approval or informed consent was required 
under Dutch law. All patients (n=13,029) undergoing surgical resection 
for primary rectal cancer between January 1st 2009 and December 
31th, 2013, and registered in the DSCA before March 15, 2014, were 
evaluated. Patients with multiple synchronous tumors with at least one 
tumor located in the rectum were included. Patients who underwent a 
local excision with or without completion TME surgery were excluded 
(n=241). In addition, patients with a complete pathological response 
(ypT0) on neo-adjuvant (chemo)radiotherapy were excluded as well 
(n=610). Minimal data requirements to consider a patient eligible 
for analyses were information on tumor location and date of surgery. 
Baseline characteristics of the study population and treatment 
characteristics are displayed per year in table 1. 
Circumferential resection margin
The mean percentage of reported CRM as well as the reported CRM rate 
per hospital for each year of the study period were calculated. CRM was 
considered positive if tumor cells were present within 1mm from the 
inked margin according to the definition of the Dutch guideline.(10) 
CRM involvement was only calculated for patients with a reported CRM. 
The mean percentage of CRM involvement as well as the percentage of 
CRM involvement per hospital was calculated for each year.  
Statistical analyses
Differences in baseline characteristics between different years of the 
study period were analyzed using a Chi square test. A p-value of less 
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than 0.05 was considered statistically significant. Potential predictors 
of CRM involvement were determined in a univariable analysis. 
Variables with a significance level of p<0.1 in univariable analysis 
were subsequently included in a multivariable logistic regression 
model as categorical variables. To analyze the possible effect of the 
DSCA on CRM involvement, the year of DSCA registration was added 
as an ordinal variable to the multivariable model. A scatterplot with 
each dot representing an individual hospital was used to visualize the 
hospital variation in CRM reporting for the years 2009, 2011 and 2013. 
The number of patients who underwent a resection for rectal cancer 
is plotted on the x-axis and the percentage of patients with a reported 
CRM on the y-axis. The overall mean percentage is represented as a 
horizontal line. 
A funnel plot was used to visualize the hospital variation in casemix 
corrected CRM involvement for the years 2009, 2011 and 2013. 
Variables included in this casemix correction for CRM involvement 
included type of resection, laparoscopic resection, emergency surgery 
and pathological T classification. The number of patients with a 
reported CRM is plotted on the x-axis and the percentage of CRM 
involvement on the y-axis. The overall average CRM involvement is 
represented by a horizontal line with its 95% and 99% confidence 
limits, based on a Poisson distribution, varying in relation to the 
population size of each hospital. To evaluate the linear effect of year 
of registration on CRM involvement, we performed a linear-by-linear 
association test. Statistical analyses were performed in PASW Statistics, 
version 20 (SPSS inc., Chicago, IL). 
RESULTS
Patient and treatment characteristics
A total of 12,178 patients, registered by 91 hospitals, were included 
for analysis. Patient, tumor and treatment characteristics are displayed 
in table 1. There was a decrease in unspecified clinical T-classification 
(p<0.001). The use of MRI as preoperative imaging technique 
increased (p<0.001) and so did the percentage of patients who were 
preoperatively discussed in a multidisciplinary team (MDT) meeting 
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(p<0.001). There was a peak incidence in the use of neoadjuvant therapy 
in 2011, and was still above 80% in 2013. There was an increase in 
the use of short course radiotherapy with delayed (>3 weeks) surgery 
(SCRT-DS) and chemoradiotherapy (CRT), both with a potential 
downsizing effect. The use of laparoscopic surgery doubled during this 
5-year period; from 33 percent in 2009 to 66 percent in 2013 (p<0.001). 
Non-elective resections decreased to 1.5 percent (p<0.001). 
Reporting of CRM
Figure 1 shows the mean percentage of patients with a reported 
CRM per year and displays the variation on this parameter between 
hospitals in 2009, 2011 and 2013. In 2009, the mean reported CRM 
rate was 52.7 percent, which varied from 0 to 100 percent between 
individual hospitals. The mean percentage of patients with a reported 
CRM increased to 94.2 percent in 2013 and inter-hospital variation 
decreased (range 33 to 100% in 2013). Baseline characteristics between 
patients with a reported and unreported CRM are displayed in Table 
2, which shows the percentage of patients without a reported T and N 
classification is higher amongst patients without a reported CRM than 
amongst patients with a reported CRM. 
CRM involvement
In 2009, the mean rate of CRM involvement was 14.2 percent in patients 
with a reported CRM (Table 3). In 2013, the mean percentage of CRM 
involvement was 5.6 percent in the 94 percent of patients with a 
reported CRM. Figure 2a-c shows the variation of CRM involvement 
among the Dutch hospitals in the years 2009, 2011 and 2013. The mean 
percentage of patients with an involved CRM was significantly lower 
in 2013 compared to 2009 (p<0.001). Furthermore, inter-hospital 
variation has decreased since the start of the DSCA (range 0 – 90 % in 
2009, range 0 – 22 % in 2013). None of the hospitals were a negative 
outlier, however, due to low annual numbers of rectal cancer resections 
per hospital per year, confidence intervals are wide. There was a 
significant effect of year of DSCA registration on CRM involvement in the 
linear by linear association test (p=0.005).
Predictors of CRM involvement
Table 4 displays the univariable and multivariable analysis of potential 
predictors for CRM involvement, including the year of DSCA registration. 
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In multivariable analysis the year of DSCA registration remained a 
significant influence on CRM involvement, with an odds ratio of 0.47 
for registration year 2013 compared to 2009. Together with the year 
of DSCA registration, clinical T classification, procedure, approach, 
setting and pathological T classification were of significant influence 
on CRM involvement. To consider the correlation in the multivariate 
model between clinical and pathological T classification we repeated 
the multivariable analysis without pathological T classification; results 
however remained unchanged (data not shown). 
DISCUSSION
After the introduction of the DSCA as a quality assurance initiative 
in the Netherlands, there has been a dramatic improvement in the 
percentage of patients with a reported CRM in rectal cancer surgery. 
Alongside this improvement there has been a major decrease of  
CRM involvement, which is known to have a significant effect on the 
long-term outcomes of patients with rectal cancer. Such a substantial 
progress in the quality of rectal cancer care has not been observed 
since the introduction and standardization of the TME technique and 
the concomitant use of neo-adjuvant therapy.(3) Improvement in CRM 
reporting is almost exclusively attributable to the national audit, and 
the present multivariable analysis also suggests that the DSCA was a 
driving force behind the significant increase in tumor free resection 
margins. 
Population based studies and other national audits on rectal cancer 
confirmed that the CRM, as an important measure for the quality of 
surgical resection, was often lacking in the pathology report.(11-14) 
Swellengrebel et al. performed a population study on the value of 
multidisciplinary team meetings in the Netherlands between 2006 
and 2008, right before the start of the DSCA, and showed that only 61 
percent of patients had a reported CRM.(15) This is substantially lower 
than the 97 percent reported CRM rate in the Dutch TME trial (1996-
1999), confirming again that a trial setting does not represent routine 
daily practice. But why was the standardized pathology reporting from 
the TME trial not implemented in the Netherlands? This is especially 
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important to ask given the numerous publications from our country 
at that time showing that CRM is one of the most important outcome 
parameters in rectal cancer.(4, 16-19) Apparently, confronting the 
individual hospitals with their data, benchmarking their outcome, and 
making CRM reporting a quality indicator that is made available to 
external parties is what eventually does lead to practice changing. The 
present analysis shows that quality indicators play an important role in 
identifying quality concerns and variation, and enable targeting quality 
improvement projects.
Other countries with a national audit on rectal cancer, for example the 
United Kingdom, also reported on CRM related quality indicators.(20) 
A decrease in CRM involvement have been observed by the National 
Bowel Cancer Audit Programme (NBOCAP) in the UK, although only a 
minor improvement in CRM reporting was found with still more than 
30 percent of patients without a reported CRM in 2013. Remarkably 
similar results as observed in the Netherlands were found by a regional 
Quality Initiative in Canada in a population of 1.3 million inhabitants 
for whom colorectal cancer surgery is provided in eight community 
hospitals and three teaching hospitals.(21) During 2-yearly voluntary 
workshops, quality markers were selected by the participating surgeons, 
together with the commencement of improvement interventions such as 
auditing and feedback, preoperative multidisciplinary consultation and 
a system event reporting system. In the period between 2006 and 2012, 
CRM reporting improved from 55 to 93 percent and CRM involvement 
decreased from 14 to 6 percent. In the limitations of this study, the 
authors question the generalizability of their findings. Our study proves 
that almost identical improvements can be achieved by just auditing, 
even at a national level with more than 16 million inhabitants.
This positive effect of feedback on CRM involvement has been described 
before. In the MRC CR07 trial, quality of the resection specimen was 
prospectively assessed and reported to the surgeons. As the study 
proceeded, the percentage of CRM involvement decreased significantly 
from 21 to 10 percent.(22) Evaluation of the TME specimen by the 
pathologist and CRM provide direct feedback towards the surgeon on 
the technical performance of the resection and, therefore, should be 
dedicated team members participating in multidisciplinary meetings in 
which patients are discussed postoperatively.(19) Furthermore, Quirke 
et al also pointed out the possible influence of the introduction of 
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standard preoperative MDT meetings and local staging with MRI which 
both could have led to the lowered percentage of CRM involvement in 
the MRC CR07 study. The DSCA included preoperative MR imaging and 
the discussion of patients in a preoperative MDT meeting as quality 
indicators, and improvements in both indicators have been observed 
(Table 1). As both preoperative MRI and MDT meetings were already 
an obligatory part of the diagnostic pathway for rectal cancer patients 
according to the Dutch national guidelines, the improvements can 
also be seen as an effect of the DSCA. Both factors were significantly 
associated with CRM involvement in univariable analysis, but lost 
their significance in multivariable analysis. Other changes during 
the study period that may have contributed to the decrease of CRM 
involvement in our study period are the increased use of downstaging 
radiotherapy regimens (SCRT-DS and CRT), which indeed revealed to 
be related to the risk of an involved CRM in univariable analysis, but 
not in multivariable analysis. The above-mentioned factors could also 
have slightly influenced CRM reporting. A multivariate analysis (data 
not shown) however showed a significant and independent effect of the 
year of registration on CRM reporting, when the effect was corrected for 
all these factors. The positive impact of an increased use of minimally 
invasive techniques on CRM involvement is difficult to interpret, as 
meta-analysis of randomized controlled trials revealed no difference in 
CRM involvement between laparoscopic and open TME surgery.(19)  
This finding could reflect the use of laparoscopic surgery by more 
specialized colorectal surgeons within more dedicated teams, but it 
might also be influenced by the inherent risk of selection bias within 
population studies. Although the influence of the approach on CRM 
involvement was analyzed in a multivariate model, there could be 
unmeasured factors that influenced the decision between open en 
laparoscopic resection.
There have not been other important changes in the treatment of rectal 
cancer in the Netherlands during the years covered by the present study. 
The multivariable analysis demonstrates the independent significant 
influence of the registration year on the risk of CRM involvement, 
which strenghtens the believe that the DSCA has been one of the 
leading factors in the major improvement of CRM involvement in the 
Netherlands in only a five year time period. 
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The limitation of this study is that it remains difficult to estimate to 
what extend the audit has influenced the improved outcome of CRM 
reporting and CRM involvement. Although we think we addressed the 
most important clinical changes we can’t exclude the possibility of other 
clinical changes that could have influenced these improvements and 
are not captured in the DSCA database. Furthermore we cannot exclude 
some reporting bias. Table 1 shows a disproportionate increase of mid-
rectal tumors and LAR procedures and some hospitals with low numbers 
of patients with a reported CRM might have reported relatively more 
patients with CRM involvement in the first registration years. However, 
this seems unlikely as a population based study from the Netherlands 
showed equal CRM involvement in that period.(15) Furthermore, the 
14 percent CRM involvement at the start of the DSCA is even favorable 
if compared to the 16 percent CRM involvement in the Dutch TME 
trial, especially considering the fact that the audit also includes locally 
advanced rectal cancer.(2)  
In conclusion, there has been a marked improvement in the percentage 
of patients with a reported CRM since the start of the DSCA as a national 
quality assurance program. Furthermore, there has been a significant 
decrease of patients with CRM involvement, which attributes to a better 
prognosis for these patients. Few other interventions in the care of 
rectal cancer patients have led to such magnitude of improvements 
in a relatively short period of time and it shows the value of national 
auditing as a tool for quality improvement.  
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Table 1: Baseline characteristics of patients with a resection for rectal 
cancer registered in the Dutch Surgical Colorectal Audit, 2009 – 2013. 
 Year of DSCA registration  
 2009 2010 2011 2012 2013 X2
Male 61.5% 62.2% 63.7% 61.1% 63.1% 0.291
Age      0.311
75+ 28.9% 27.0% 28.2% 28.1% 29.6%  
ASA score      0.884
III 16.9% 16.8% 17.6% 17.8% 17.3%  
BMI      0.005
30+ 13.5% 16.6% 15.2% 17.9% 16,0%  
Clinical T 
classification
     <0.001
 cT1 3.5% 3.8% 3.8% 2.7% 2.3%  
 cT2 19.2% 23.3% 23.3% 24.0% 21.2%  
 cT3 47.0% 46.6% 52.1% 55.7% 61.9%  
 cT4 9.9% 8.7% 7.9% 8.6% 9.1%  
 cTx/unknown 20.4% 17.5% 12.9% 8.9% 5.5%  
Distance tumor - 
anus
     <0.001
<=5 cm 35.8% 32.3% 34.9% 33.3% 36.2%  
6-10 cm 35.6% 39.0% 38.5% 38.9% 39.0%  
>10 cm 20.1% 20.9% 20.3% 23.0% 21.1%  
unknown 8.5% 7.8% 6.2% 4.8% 3.7%  
MRI      <0.001
yes 78.4% 83.7% 88.0% 90.2% 91.9%  
unknown 11.3% 6.7% 3.2% 1.7% 1.8%  
MDT      <0.001
yes 79.0% 90.4% 95.9% 98.1% 98.7%  
Neo-adjuvant 
therapy 
     <0.001
none 21.3% 16.9% 14.1% 18.2% 18.6%  
SCRT 41.9% 45.4% 45.7% 39.2% 35.9%  
SCRT-ds 3.5% 3.7% 4.4% 6.3% 8.8%  
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CRT 33.0% 33.9% 35.5% 36.3% 36.5%  
other 0.3% 0.1% 0.3% 0.0% 0.2%  
Procedure      <0.001
LAR 58.0% 61.5% 65.8% 70.5% 68.9%  
APR 31.6% 29.4% 29,4% 26.6% 28.6%  
other/non-specified 10.4% 9.2% 4.8% 2.8% 2.6%  
Approach      <0.001
Laparoscopic 33.2% 36.2% 43.2% 54.7% 65.5%  
Setting      <0.001
Non-elective 5.4% 2.6% 1.7% 2.3% 1.5%  
Pathological T 
classification
     <0.001
(y)pT1 7.4% 7.1% 8.3% 8.5% 8.8%  
(y)pT2 28.5% 32.0% 33.9% 32.8% 33.3%  
(y)pT3 46.8% 47.7% 49.1% 51.9% 51.9%  
(y)pT4 6.6% 5.8% 5.2% 4.9% 4.6%  
(y)pTX/unknown 10.6% 7.3% 3.5% 2.0% 1.5%  
Pathological N 
classification
     <0.001
pN0 58.7% 61.5% 61.0% 62.6% 63.0%  
pN1 20.2% 23.8% 25.8% 23.8% 24.5%  
pN2 12.8% 11.6% 10.4% 12.6% 11.8%  
pNx/unknown 8.3% 3.0% 2.7% 1.1% 0.8%  
Metastatic disease 8.3% 7.8% 7.5% 8.2% 7.5% 0.806
Continuation of Table 1
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Table 2: Baseline characteristics of tumors with and without a reported 
CRM. 
 Reported CRM  
 No Yes X2
Clinical T classification   <0.001
 cT1 5.5% 2.5%  
 cT2 21.2% 22.7%  
 cT3 39.2% 57.0%  
 cT4 7.8% 9.1%  
 cTx/unknown 26.2% 8.7%  
Neo-adjuvant therapy   <0.001
none 29.9% 14.2%  
SCRT 37.9% 42.6%  
SCRT-ds 2.9% 6.2%  
CRT 29.0% 36.9%  
other 0.3% 0.2%  
Procedure   <0.001
LAR 62.9% 66.0%  
APR 24.1% 30.4%  
other/non-specified 13.0% 3.6%  
Pathological T classification   <0.001
(y)pT1 10.2% 7.4%  
(y)pT2 29.5% 33.0%  
(y)pT3 38.7% 52.8%  
(y)pT4 6.8% 5.0%  
(y)pTX/unknown 14.9% 1.8%  
Pathological N classification   <0.001
pN0 61.4% 61.5%  
pN1 21.0% 24.5%  
pN2 9.4% 12.5%  
pNx/unknown 8.1% 1.4%  
Metastatic disease 8.1% 7.8% 0.631
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Table 3. Reported CRM and CRM involvement from 2009 to 2013. 




 n n % n %
2009 2056 1084 52.7 154 14.2
2010 2447 1531 62.6 185 12.1
2011 2462 1956 79.4 177 9.0
2012 2692 2480 92.1 197 7.9
2013 2521 2375 94.2 134 5.6
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Table 4. The influence of the year of DSCA registration on CRM involvement 
in a multivariable analysis.
Variable (ref) Univariate Multivariate
 p OR CI
   Lower Upper
Clinical T-classification (cT1) <0.001    
cT2  1.33 0.67 2.65
cT3  1.21 0.62 2.36
cT4  1.33 0.65 2.68
cTx  0.95 0.47 1.96
Distance tumor - anus (>10cm) <0.001    
≤ 5 cm  1.16 0.90 1.51
6-10 cm  0.95 0.76 1.18
unknown  1.09 0.75 1.59
MRI (no) 0.059    
yes  1.04 0.80 1.35
MDT (no) 0.055 0.96 0.68 1.36
yes     
Down-sizing radiotherapy (no) <0.001    
yes  1.15 0.96 1.37
Procedure (LAR) <0.001    
APR  1.49 1.21 1.84
other / non-specified  1.49 1.02 2.16
Approach (open) <0.001    
laparoscopic  0.82 0.70 0.97
Setting (elective) <0.001    
urgent  2.22 1.43 3.47
Pathological T-classification 
((y)pT1)
<0.001    
(y)pT2  1.52 0.82 2.81
(y)pT3  6.35 3.54 11.40
(y)pT4  29.19 15.68 54.33
(y)pTx  2.43 1.00 5.90
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Year of DSCA registration 
(2009)
<0.001    
2010  0.97 0.75 1.25
2011  0.75 0.58 0.96
2012  0.67 0.52 0.86
2013  0.47 0.35 0.61




Figure 1a-c. Scatterplots showing the mean percentage and hospital 




Figure 2a-c. Funnelplot showing the case-mix corrected percentage of 
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ABSTRACT 
Background: The rate of preoperative radiotherapy (RT) for rectal 
cancer in the Netherlands has been the highest among European 
countries. Revision of the national guideline on colorectal cancer, 
officially published in 2014, specifically focussed on the indication for 
RT and MRI criteria to evaluate mesorectal lymph nodes. The objective 
of this study was to evaluate implementation of the revised guideline 
using a national audit. 
Methods: Data of the Dutch Surgical Colorectal Audit (DSCA) between 
2009 and 2014 were used to evaluate RT use and RT regimen for 
relevant subgroups of cM0 rectal cancer patients, as well as accuracy of 
preoperative MRI.
Results: 14,018 patients were included for analysis. Overall RT use in 
cT1-4N0-2M0 stage ranged from 81.4% to 84.2% between 2009 and 
2013, and decreased to 64.4% in 2014. The absolute decrease in RT 
use from 2013 to 2014 for cT1N0, cT2N0 and cT3N0 stage was 32.8%, 
43.5% and 31.6%, respectively. Short course RT with delayed surgery 
was used as an alternative to chemoradiotherapy up to 2013 in 30.6% of 
patients over 80 years, and in 12.1% of patients with an ASA score > 2; 
these percentages increased to 45.8% and 19.9% in 2014, respectively. 
Specificity of MRI for N-stage decreased from 82.9% in 2009 to 62.9% in 
2013, with an increase to 73.2% in 2014. 
Conclusion: The revised national guideline on colorectal cancer was 
rapidly implemented in the Netherlands with a substantial decrease in 
RT use for low risk resectable rectal cancer, and increased specificity of 




Preoperative radiotherapy (RT) in rectal cancer patients has been shown 
to reduce local recurrence rates, but this oncological improvement 
should be weighed against radiotherapy related morbidity.1, 2 The use 
of RT in rectal cancer management in the Netherlands was published 
by van Leersum et al. in 2013.3 RT use in the Netherlands appeared 
to be high compared to other countries, with an overall rate of more 
than 80%. Even the majority of stage I rectal cancer patients received 
preoperative RT.3, 4
In 2012, a revision of the national guideline on colorectal cancer was 
initiated with RT indications as one of the primary topics. The revised 
guideline was sent to all the members of the involved national societies 
with the possibility to comment on this version before September 
2013. The revised guideline was officially published in June 2014.5 
RT is not recommended for low risk resectable rectal cancer in the 
revised guideline, defined as a cT1-3N0 stage with extramural invasion 
≤5 mm and a distance to the mesorectal fascia (MRF) >1 mm based on 
the preoperative MRI. In order to reduce overtreatment with RT based 
on false-positive cN+ stage, MRI criteria to evaluate mesorectal lymph 
nodes were adapted. Furthermore, the use of short course radiotherapy 
with delayed surgery (SCRT-ds) was recommended as an alternative to 
chemoradiotherapy (CRT) for the older, more fragile patient.  
The Dutch Surgical Colorectal Audit (DSCA) was founded in 2009 and 
evaluates and reports on the quality of care of primary colorectal  
cancer surgery. It provides periodic feedback to all hospitals in the 
Netherlands on patient, tumor, and treatment characteristics and a set 
of predefined national quality measures.6 The objective of this study 
was to evaluate the use of preoperative RT for rectal cancer in the 
Netherlands and the impact of the revised national guideline through 
an analysis of the DSCA data by comparing data of 2014 with data in the 
period between 2009 and 2013. Furthermore, the aim was to determine 
the diagnostic accuracy of preoperative MRI for nodal staging during the 




Data were derived from the Dutch Surgical Colorectal Audit  
(DSCA), a disease specific national audit.6 This audit collects 
information on patient, tumor, treatment and 30 day and in-hospital 
outcome characteristics of all patients undergoing a resection for 
primary colorectal carcinoma in the Netherlands. The dataset is based 
on evidence-based guidelines and has been cross-checked on a yearly 
basis with data from the Netherlands Cancer Registry (NCR).7 All Dutch 
hospitals participate and the dataset contains approximately 97% of all 
patients that are surgically treated for a primary colorectal carcinoma 
in the Netherlands. Details of the DSCA regarding data collection and 
methodology have been published previously.6, 8
Patient selection 
For this study, no ethical approval or informed consent was required 
under Dutch law. All patients (n=16,238) undergoing surgical resection 
for primary rectal cancer between January 1st, 2009 and December 
31th, 2014, and registered in the DSCA before April 15th, 2015, were 
evaluated. Minimal data requirements to consider a patient eligible for 
analysis were information on tumor location, date of surgery and 30-
day mortality (n=16,128). For the purpose of this study, patients who 
underwent a transanal resection  
(n=392) were excluded. Furthermore, the heterogenous group of 
patients with synchronous distant metastases (n=1177) and multiple 
synchronous colorectal tumors (n=616) were excluded, resulting in 
14,018 patients with a solitary tumor in the rectum and a cM0 stage.9 
Preoperative therapy
The DSCA registers different regimens of RT: short course radiotherapy 
(SCRT), chemoradiotherapy (CRT), and long course radiotherapy 
without concomitant chemotherapy (LCRT). As indications of LCRT 
are similar to CRT, we added these patients (n=315) to the CRT group 
for our analyses. Because of its clinical implications, the interval from 
SCRT to surgery was determined and a subgroup of delayed surgery was 
defined when the interval from end of RT to surgery was more than 2 
weeks (SCRT-ds). Because only the start date of RT is available in the 
DSCA, the time interval between end of RT and surgery was calculated 
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by subtracting 7 days from the interval between start of RT and surgery. 
When the interval to surgery for patients with SCRT was unknown 
(n=1335, 9.5%) it was considered as less than 2 weeks as it is standard 
practice to proceed to surgery within a few days after the last dose of 
SCRT.5, 10 SCRT-ds and CRT both have a downsizing effect on the tumor. 
Therefore, these modalities are referred to as down-staging therapy.11
Statistical analysis
The draft version of the revised colorectal cancer guideline became 
publicly accessible in September 2013 and was already used in the few 
months thereafter by many MDTs before the definitive version was 
published in June 2014. Therefore, we choose January 2014 as the cut-
off to determine the impact of the revised colorectal cancer guideline. 
The overall percentage of RT use in patients with a cT1-4N1-2M0 stage 
was determined for each year throughout the study period, as well as 
the use of SCRT, SCRT-ds and CRT for different cTN categories separately. 
Extramural invasion is not registered in the DSCA, which did not allow 
for separate analyses for cT3a-d stages. Furthermore, the use of CRT and 
SCRT-ds was analysed in patients with locally advanced rectal carcinoma 
(cT3 with a distance to mesorectal fascia of less than 1 mm, or cT4, and/
or cN2 according to the MRI) within stratified subgroups based on age 
and ASA score.  
Revised MRI criteria to determine cN stage were evaluated in patients 
in whom no down-staging effect was expected (TME surgery alone or 
SCRT with short interval to surgery). Patients without preoperative MRI 
were excluded. The cN stage was compared with pN stage as golden 
standard, and sensitivity, specificity, positive and negative predictive 
value were calculated for each year and plotted to analyse time trends 
during the study period. We calculated 95% and 99% confidence 
intervals for each of these values in order to detect significant changes 
of these values throughout the years. P-values are displayed accordingly 
(p<0.05 or p<0.01). For the purpose of this analysis, cN1 and cN2 were 
grouped together as cN+, and patients with an unknown cN or cT stage 
were excluded. Clinical suspicion of a positive lymph node on MRI was 
defined as a diameter > 5 mm in the old guideline. The revised criteria 
are: diameter ≥ 9 mm; diameter 5-9 mm and two of three morphological 
criteria consisting of irregular border, heterogeneous texture and round 
shape; diameter < 5 mm and all three morphological criteria. In case of 
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doubt, the revised guideline recommends to classify as cN0. Statistical 
analyses were performed in PASW Statistics, version 20 (SPSS inc., 
Chicago, IL)
RESULTS
Patient, tumor and treatment characteristics
A total of 14,018 eligible rectal cancer patients were registered by 
92 hospitals between January 2009 and December 2014. Table 1 
shows the baseline characteristics of the study population. A majority 
of 11,989 (85.5%) patients had a registered cT and cN stage; 1362 
(9.7%) and 1707 (12.2%) patients did not have a registered cT or cN 
stage, respectively. cT stage was not registered for 18.6% of patients 
in 2009, which improved to 3.5% in 2014 (p=<0.001). For pT stage, 
these percentages were 10.7% and 1.0% (p=<0.001), respectively. cN 
stage was not registered for 24.6% of patients in 2009, which improved 
to 3.9% in 2014 (p=<0.001). For pN stage, these percentages were 
7.8% and 0.7% (p=<0.001), respectively. The use of preoperative MRI 
increased during the study period from 81.1% in 2009 to 94.6% in 2014 
(p=<0.001). 
Trends in time for preoperative radiotherapy
The overall percentage of RT use in cT1-4N0-2M0 stage was 81.4% 
to 84.2% between 2009 and 2013 and decreased to 64.4% in 2014 
(p=<0.001) (Figure 1). This decrease was mainly seen in low risk 
resectable rectal cancer. Figure 1 shows that use of RT increased until 
2011 for cT1-4N0-2M0 stages, with decreasing RT rates since 2012 
that became most pronounced in 2014. The absolute decrease in RT use 
from 2013 to 2014 was 32.8%, 43.5% and 31.6% for cT1N0, cT2N0 and 
cT3N0 (p=<0.001), respectively.
Figure 2 shows preoperative therapy for all cTN categories for patients 
without metastasized disease in the period from 2009 -2013 and 2014. 
The use of SCRT decreased for almost all stages, with the greatest 
decrease in the use of SCRT for patients with a cT1-3N0 tumor. SCRT-
ds was used more frequently for cT3-4N0-2 stages in 2014 (p=<0.001). 
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Overall CRT use increased from 34.7% in 2009 up to 41.3% in 2013 
(p=<0.001); MRI based diagnosis of cN2 stage increased from 10.5% to 
24.4% during this period (p=<0.001). There was a deviation from this 
trend in CRT use with a decrease to 34.3% in 2014 (p=<0.001); clinical 
diagnosis of N2 stage slightly decreased to 23.1% in 2014 (ns).
For patients with locally advanced rectal carcinoma the use of SCRT-
ds instead of CRT increases for patients of higher age and with an ASA 
score of III+ (figure 3a and b). Up to 2013, 30.6% of these patients that 
were older than 80 years received SCRT-ds; this percentage was 12.1% 
for these patients with an ASA score of three or higher. In 2014 these 
percentages increased to 45.8% and 19.9% (p=<0.001). 
Clinical N stage on preoperative MRI
Up to 2013, a 20% increase in clinical diagnosis of cN1-2 disease was 
observed, from 41.4% to 61.4% (p=<0.001). After guideline revision, 
the opposite trend was seen with an increase of cN0 from 38.6 to 45.5% 
in 2014, and a corresponding decrease in patients with cN1-2 disease 
(p=<0.001). The sensitivity of MRI to determine cN1-2 disease showed 
a steady increase from 37.4% in 2009 to 55.4% in 2014 (p<0.01). The 
positive predictive value showed a decrease up to 2013 and a reversed 
deviation from this trend in 2014 with an increase from 42.7% to 47.8% 
after guideline revision (figure 4) (ns). The specificity decreased from 
82.9% to 62.9% in 2013 with an increase to 73.2% in 2014 (p<0.01). 
The negative predictive value slightly improved from 73.8% in 2013 to 
78.8% after guideline revision (p<0.05). 
DISCUSSION 
This population-based study on radiotherapy use for non-metastatic 
rectal cancer revealed a clear impact of the revised national 
colorectal cancer guideline immediately after it became available to 
the community. The most remarkable change in daily practice was 
abolishing the use of RT in cT1N0 rectal cancer in the Netherlands, with 
significant reductions in cT2-3N0 stages. A deviation from the trend in 
the use of RT in low-risk resectable rectal cancer was already observed 
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in 2012 (figure 1), based on increased insight by auditing and raising 
awareness of being a European exception regarding RT use for this 
patient group.3 Guideline revision appeared to be the ultimate tool to 
rapidly change clinical practice. Besides adapted indications, the overall 
reduction in RT use can also be attributed to the adapted criteria for 
evaluation of the mesorectal lymph nodes on MRI, which resulted in a 
decrease of false-positive results in 2014 (figure 4). 
Multiple European countries have initiated rectal cancer audits. 
Subsequent improvements in rectal cancer care were achieved 
at a national level by going through the audit cycle of measuring 
performance, giving feedback and initiation of interventions, and by 
identification of best practices and underperforming hospitals.12-15 In 
addition, comparisons between these audits provided also valuable 
information by showing substantial variation in outcomes and 
treatment strategies between countries.4, 16, 17 DSCA data confirmed 
that rectal cancer patients in the Netherlands were more often treated 
with preoperative RT compared to other European countries.3 This 
was based on the previous Dutch rectal cancer guideline from 2008, 
which recommended SCRT for all patients with resectable rectal cancer 
except for T1N0 and proximal T2N0 tumors. The Dutch TME trial with 
quality controlled implementation of TME surgery, radiotherapy and 
pathological examination in the Netherlands in the 1990s dictated the 
treatment of rectal cancer in the decade thereafter and constituted the 
basis of the national guideline. The experimental arm of the TME trial 
became routine rectal cancer management. In the absence of reliable 
methods to diagnose a cT1N0 stage, even these early cancers were 
irradiated with increasing rates of up to 66% in 2011, which was not in 
accordance with the guideline. 
Before MRI became a standard part of the preoperative work up, the 
risk of local recurrence was difficult to estimate, which hampered 
implementation of a patient tailored use of RT. The Mercury trial 
showed that the risk of local recurrence could preoperatively be 
estimated by MRI and demonstrated that low risk resectable rectal 
cancer was safely treated by TME surgery alone given a 3% 5-year local 
recurrence rate.18 Especially in light of these published data, Dutch 
practice stressed the need for a revision of the national guideline. The 
discrepant policy regarding RT use in early stages of rectal cancer in 
the Netherlands was published in an international journal, presented at 
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national gatherings and broadly discussed in the annual report of the 
DSCA.3, 15 This is most likely the explanation for the observed break in 
the trend in 2012 and explains why the multidisciplinary rectal cancer 
teams were able to rapidly implement the renewed national guideline in 
2014. National auditing is therefore not only useful as a benchmarking 
tool but also creates an informed professional environment in which 
new guidelines can be introduced and thereafter tested on their 
implementation. 
Oncological benefit of RT has to be weighed against short and long-term 
negative effects of radiotherapy.19-21 For older patients or patients with 
comorbidity it is especially important to weigh the potential oncological 
benefit and consider the risks of acute toxicity. The Stockholm III trial 
introduced a new downstaging regimen; short course radiotherapy with 
delayed surgery (SCRT-ds). This is an alternative down-staging regimen 
with less acute toxicity compared to CRT and is now mentioned as such 
in the revised guideline. However, SCRT-ds was already used for several 
indications including elderly frail people with locally advanced rectal 
cancer before that time (Figure 3), showing that changes in clinical 
practice sometimes precede guideline recommendations. After guideline 
revision, the use of SCRT-ds in high-risk patients further increased to a 
substantial level.
In contrast to the Mercury study group, clinical N stage is still an 
important factor when deciding on preoperative RT in the Netherlands. 
Being aware of the restricted accuracy of MRI for nodal staging, it 
was decided to define more strict criteria for suspicion of lymph node 
involvement in order to reduce the risk of over-staging.22, 23 Our results 
show that the adapted MRI protocol for lymph node assessment in 
the national guideline did seem to have an influence on the amount of 
patients with false positive lymph nodes at clinical staging, leading to 
less patients with low-risk rectal cancer undergoing RT. Compared to 
2013, the specificity, positive predicted value, and negative predictive 
value increased, while the sensitivity remained at the same level. The 
percentage of cN2 was steadily increasing up to 2013, but slightly 
decreased in 2014. This could be, amongst others, the explanation 
for the decrease in the percentage of CRT use from 2013 to 2014. 
In the near future, higher accuracy of MRI based nodal staging is 
expected from lymph node-specific contrast agents such as ultrasmall 
superparamagnetic particles of iron oxide (USPIO).24 At present 
however, the FDA and EMEA have not approved USPIO contrast. 
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Limitations of the present study are related to the limitations of the 
DSCA dataset. It would have been interesting to analyse the use of RT 
in patients with a cT3 tumor depending on the extent of extramural 
invasion in 2014, because this has become an additional criterion in the 
revised guideline. The DSCA unfortunately does not register whether 
extramural invasion was seen on preoperative MRI, but this will be 
added to the dataset of 2016. Similarly, the distance of the tumor to the 
MRF based on the preoperative MRI was only registered from 2012 on, 
with registration rates of 57.8% in 2012 and still only 73.9% in 2014. 
Availability of these data would have enabled more detailed analysis of 
guideline adherence in cT3 stage rectal cancer. 
In conclusion the revised national guideline on colorectal cancer was 
rapidly implemented in the Netherlands and led to a fast decrease in 
the use of RT for patients with low risk resectable rectal cancer and a 
decrease in patients with false positive cN1-2 disease on preoperative 
MRI. It is believed that the national clinical audit has played an 
important role in the observed changes in clinical practice. The rapid 
implementation of the revised national guideline on colorectal cancer is 
a good example of the usage of audit data to instigate national practice 




1. Adjuvant radiotherapy 
for rectal cancer: a systematic 
overview of 8,507 patients from 
22 randomised trials. Lancet 
2001; 358(9290):1291-304.
2. Kapiteijn E, Marijnen CA, 
Nagtegaal ID, et al. Preoperative 
radiotherapy combined with 
total mesorectal excision for 
resectable rectal cancer. N Engl J 
Med 2001; 345(9):638-46.
3. van Leersum NJ, Snijders 
HS, Wouters MW, et al. Evaluating 
national practice of preoperative 
radiotherapy for rectal cancer 
based on clinical auditing. Eur J 
Surg Oncol 2013; 39(9):1000-6.
4. Mroczkowski P, Ortiz 
H, Penninckx F, et al. European 
quality assurance programme 
in rectal cancer--are we ready 
to launch? Colorectal Dis 2012; 
14(8):960-6.
5. http://www.oncoline.nl. 
6. Van Leersum NJ, 
Snijders HS, Henneman D, et al. 
The Dutch surgical colorectal 
audit. Eur J Surg Oncol 2013; 
39(10):1063-70.
7. Dutch Institute for 
Clinical Auditing. Annual Reports 
2012. http://www.clinicalaudit.
nl. 
8. Kolfschoten NE, Marang 
van de Mheen PJ, Gooiker GA, 
et al. Variation in casemix 
between hospitals treating 
colorectal cancer patients in the 
Netherlands. Eur J Surg Oncol 
2011; 37(11):956-63.
9. van Leersum NJ, 
Aalbers AG, Snijders HS, et 
al. Synchronous colorectal 
carcinoma: a risk factor in 
colorectal cancer surgery. Dis 
Colon Rectum 2014; 57(4):460-6.
10. Marijnen CA, Nagtegaal 
ID, Klein Kranenbarg E, et al. No 
downstaging after short-term 
preoperative radiotherapy in 
rectal cancer patients. J Clin 
Oncol 2001; 19(7):1976-84.
11. Pettersson D, Holm T, 
Iversen H, et al. Preoperative 
short-course radiotherapy with 
delayed surgery in primary 
rectal cancer. Br J Surg 2012; 
99(4):577-83.
12. Bulow S, Harling H, 
Iversen LH, et al. Improved 
survival after rectal cancer in 
Denmark. Colorectal Dis 2010; 
12(7 Online):e37-42.
96
13. Wibe A, Moller B, 
Norstein J, et al. A national 
strategic change in treatment 
policy for rectal cancer-
-implementation of total 
mesorectal excision as routine 
treatment in Norway. A national 
audit. Dis Colon Rectum 2002; 
45(7):857-66.
14. Pahlman L, Bohe M, 
Cedermark B, et al. The Swedish 
rectal cancer registry. Br J Surg 
2007; 94(10):1285-92.
15. Annual report 2013, the 
Dutch Surgical Colorectal Audit.
16. van den Broek CB, 
van Gijn W, Bastiaannet E, et 
al. Differences in preoperative 
treatment for rectal cancer 
between Norway, Sweden, 
Denmark, Belgium and the 
Netherlands. Eur J Surg Oncol 
2014; 40(12):1789-96.
17. De Angelis R, Sant M, 
Coleman MP, et al. Cancer survival 
in Europe 1999-2007 by country 
and age: results of EUROCARE--5-a 
population-based study. Lancet 
Oncol 2014; 15(1):23-34.
18. Taylor FG, Quirke P, 
Heald RJ, et al. Preoperative high-
resolution magnetic resonance 
imaging can identify good 
prognosis stage I, II, and III rectal 
cancer best managed by surgery 
alone: a prospective, multicenter, 
European study. Ann Surg 2011; 
253(4):711-9.
19. Chen TY, Wiltink LM, 
Nout RA, et al. Bowel function 14 
years after preoperative short-
course radiotherapy and total 
mesorectal excision for rectal 
cancer: report of a multicenter 
randomized trial. Clin Colorectal 
Cancer 2015; 14(2):106-14.
20. Marijnen CA, van de Velde 
CJ, Putter H, et al. Impact of short-
term preoperative radiotherapy 
on health-related quality of 
life and sexual functioning in 
primary rectal cancer: report of 
a multicenter randomized trial. J 
Clin Oncol 2005; 23(9):1847-58.
21. Stephens RJ, Thompson 
LC, Quirke P, et al. Impact of short-
course preoperative radiotherapy 
for rectal cancer on patients’ 
quality of life: data from the 
Medical Research Council CR07/
National Cancer Institute of 
Canada Clinical Trials Group C016 




22. Lahaye MJ, Engelen 
SM, Nelemans PJ, et al. Imaging 
for predicting the risk factors-
-the circumferential resection 
margin and nodal disease--of local 
recurrence in rectal cancer: a 
meta-analysis. Semin Ultrasound 
CT MR 2005; 26(4):259-68.
23. Bipat S, Glas AS, Slors FJ, 
et al. Rectal cancer: local staging 
and assessment of lymph node 
involvement with endoluminal 
US, CT, and MR imaging--a 
meta-analysis. Radiology 2004; 
232(3):773-83.
24. Lahaye MJ, Engelen 
SM, Kessels AG, et al. USPIO-
enhanced MR imaging for nodal 
staging in patients with primary 
rectal cancer: predictive criteria. 




Table 1: Baseline characteristics of patients with a resection for rectal 
cancer registered in the Dutch Surgical Colorectal Audit, 2009 – 2014. ASA = 
Association of Anaesthesiologists; BMI = Body Mass Index; MRI = Magnetic 
Resonance Imaging; MDT = Multidisciplinary team meeting; SCRT = Short 
course radiotherapy; SCRT-ds = Short course radiotherapy with delayed 
surgery; LAR = Low anterior resection; APR = Abdominoperineal resection. 
 Count Percentage
Male 8713 62.2
Age   
75+ 3955 28.2
ASA score   
III+ 2329 16.6
BMI   
30+ 2050 16.7
Clinical T classification   
 cT1 478 3.4
 cT2 3305 23.6
 cT3 7713 55.0
 cT4 1160 8.3
 cTx 1362 9.7
Clinical N classification   
 cN0 5761 41.1
 cN1 4172 29.8
 cN2 2378 17.0
 cNx 1707 12.2
Distance tumor - anus   
<=5 cm 5001 36.3
6-10 cm 5270 38.2
>10 cm 2939 21.3




MDT   
yes 13268 94.6









Setting   
Non-elective 257 1.8






Pathological N classification   
 pN0 9302 66.4
 pN1 3041 21.7
 pN2 1356 9.7
 pNx 319 2.3
CRM involvement 776 6.7
10+ retrieved lymphnodes 10079 71.9
Continuation of Table 1
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Figure 1: Use of preoperative radiotherapy for rectal cancer in the 
Netherlands for different clinical stages, 2009 – 2014.
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Figure 2a, b: Use of preoperative radiotherapy according to tumor and 
nodal stage (cM0) in the period between 2010 -2013(a) and in 2014(b). 
SCRT = short course radiotherapy; SCRT-ds = short course radiotherapy with 
delayed surgery; CRT = chemoradiotherapy. 
102
Figure 3a and b: Use of preoperative therapy in stratified groups based on 
age and ASA classification in 2009-2013 (a) and 2014 (b). 
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Figure 4: Sensitivity, specificity, positive predictive value (PPV), and 
negative predictive value (NPV) for clinical mesorectal lymph node staging 
based on MRI (cN0 and cN1-2 versus pN0 and pN1-2 in patients not 




REDUCED 30 DAY MORTALITY AFTER LAPAROSCOPIC 
COLORECTAL CANCER SURGERY: A POPULATION BASED 
STUDY FROM THE DUTCH SURGICAL COLORECTAL AUDIT 
(DSCA).
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ABSTRACT
Objective: To evaluate the impact of a laparoscopic resection on 
postoperative mortality after colorectal cancer surgery.
Summary background data: The question whether laparoscopic 
resection (LR) compared to open resection (OR) for colorectal cancer 
influences the risk of postoperative mortality remains unresolved. 
Several meta-analyses showed a trend, but failed to reach statistical 
significance. The exclusion of high-risk patients and insufficient power 
might be responsible for that. We analyzed the influence of LR on 
postoperative mortality in a risk-stratified comparison and secondly we 
studied the effect of LR on postoperative morbidity.
Methods: Data from the Dutch Surgical Colorectal Audit (2010 - 2013) 
was used. Homogenous subgroups of patients were defined based on 
factors influencing the choice of surgical approach and risk factors for 
postoperative mortality. Crude mortality rates were compared between 
LR and OR. The influence of LR on postoperative complications was 
evaluated using both univariable and multivariable analysis. 
Results: In patients undergoing elective surgery for non-locally 
advanced, non-metastasized colon cancer, LR was associated with a 
significant lower risk of postoperative mortality compared to OR in 
20/22 subgroups. LR was independently associated with a lower risk of 
cardiac (OR 0.73, 95% CI 0.66-0.82) and respiratory (OR 0.73, 95% CI 
0.64-0.84) complications. 
Conclusions: LR reduces the risk of postoperative mortality compared 
to OR in elective setting in patients with non-locally advanced, non-
metastasized colorectal cancer. Especially elderly frail patients seem 
to benefit because of reduced cardiopulmonary complications. These 
findings support widespread implementation of LR for colorectal cancer, 




The reduction of surgical trauma by minimally invasive techniques in 
both colon and rectal cancer surgery has been shown to result in faster 
postoperative recovery compared to conventional open surgery, without 
compromising oncological outcome.1, 2 This has been demonstrated 
with the highest level of evidence by meta-analyses of randomized 
controlled trials (RCTs). Long-term benefits of laparoscopic resection 
for colorectal cancer are better cosmetics, less incisional hernias due 
to preserved abdominal wall integrity, and less adhesion related small 
bowel obstruction.3-5 Considering costs, laparoscopic colorectal surgery 
seems to be cost-effective because of reduced hospital stay despite 
higher intra-operative costs, which may become even more pronounced 
in the long run given the lower rate of readmissions and re-operations 
for small bowel obstruction and incisional hernia.5, 6
A still unresolved question is whether a laparoscopic approach 
influences the risk of postoperative mortality after colorectal cancer 
surgery. Several meta-analyses of RCTs showed a trend towards lower 
postoperative mortality in favor of laparoscopic resection, but failed to 
reach statistical significance.1, 7, 8 The inclusion of relatively low  
risk patients and the lack of sufficient power are probably responsible 
for that. 
Population studies can solve this problem because of higher numbers 
of patients. In addition, high-risk patients with higher event rates are 
included in these studies reflecting daily practice.9-12 Therefore, the 
purpose of this population-based analysis was to compare postoperative 
mortality between laparoscopic and open resection of colorectal cancer 
in homogenous subgroups based on known operative risk factors. By 
using a risk-stratified comparison, it was intended to minimize the 
inherent risk of selection bias in population studies. Secondly we 
studied the effect of laparoscopic surgery on postoperative morbidity, 
especially cardiopulmonary complications, in order to investigate one 




Data were derived from the Dutch Surgical Colorectal Audit (DSCA), 
a disease specific national audit.13 This audit collects information 
on patient, tumor, treatment and 30 day and in-hospital outcome 
characteristics of all patients undergoing a resection for primary 
colorectal carcinoma in the Netherlands. The dataset is based on 
evidence-based guidelines and is cross-checked on a yearly basis with 
data from the Netherlands Cancer Registry (NCR).14 All Dutch hospitals 
participate, with approximately 97 percent completeness in 2012 
based on comparison with the NCR. Details of the DSCA regarding data 
collection and methodology have been published previously.13, 15
Patients
For this study, no ethical approval or informed consent was required 
under Dutch law. All patients (n=37,871) undergoing surgical resection 
for primary colorectal cancer between January 1st, 2010 and December 
31th, 2013, and registered in the DSCA before April 15th, 2014, were 
evaluated.  Minimal data requirements to consider a patient eligible for 
analysis were information on tumor location, date of surgery and 30-
day mortality (n=37,636). For the purpose of this study, patients who 
underwent transanal resection (n=244) were excluded. Furthermore, 
the heterogenous group of patients with multiple synchronous 
colorectal tumors (n=1396) were excluded.16 One hospital did not have 
reliable outcomes of postoperative mortality in 2010 and 2011 due 
to incorrect electronic input of data and corresponding patients were 
excluded (n=274). One hospital closed during 2011 and the registered 8 
patients from that year were also excluded (n=8).
Surgical approach at hospital level
Practice patterns of surgical approach for resection of colorectal cancer 
in the Netherlands in 2010 based on the DSCA have been published 
previously.12 A mean laparoscopic resection rate of 44% at patient 
level was found, with a laparoscopic resection rate ranging between 
0% and 96% at hospital level. In order to be informed about hospital 
variation in use of laparoscopic resection since then, the proportion 
of laparoscopic resections for colorectal cancer per hospital per year 
was calculated, with conversion to open surgery being included in the 
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laparoscopic group. Six hospitals didn’t have results for the full study 
period; two due to hospital closure, three hospitals had incompatible 
datasets for specific years which could not be implemented in the 
DSCA database and one due to the earlier mentioned non-plausible 
outcome on postoperative mortality. Hospitals were categorized into 
three groups; low- (0-33%), medium- (33-67%) and high- (67-100%) 
rate laparoscopic resection hospitals, according to the percentage 
of laparoscopic colorectal cancer resections in these hospitals. 
Potential differences in baseline characteristics of patient populations 
between these three categories were assessed in order to be aware of 
confounding factors determining the surgical approach. 
Data analysis and risk stratification
For the purpose of analyzing the primary aim of this study, homogenous 
subgroups were defined based on potential factors influencing 
the choice of surgical approach (locally advanced tumor, previous 
abdominal surgery, elective or emergency setting), and known risk 
factors for postoperative mortality (elective or emergency setting, age, 
ASA classification, tumor stage). Analyses were performed separately 
for colon and rectal cancer. Type of previous abdominal surgery is 
not specified in the DSCA. This may entail for example laparoscopic 
appendectomy or prior open bowel resection. For this reason, analyses 
were performed with and without including patients with previous 
abdominal surgery. Procedures were defined as an open resection (OR) 
or a laparoscopic resection (LR) based on the intentional approach 
of the resection. In this way, converted LR was included in the LR 
group. Crude mortality rates were compared between OR and LR in the 
predefined subgroups. This analysis was chosen as an alternative to 
casemix adjusted comparison between OR and LR in the whole group 
of patients, because we wanted to determine if the impact of surgical 
approach differs among groups of patients with different operative risk. 
Differences in postoperative mortality rates were analyzed using 
a chi-square test with a significance level of 0.05. A relative risk 
of postoperative mortality with 95% confidence interval and 
corresponding relative risk reduction was calculated for each subgroup. 
This analysis was repeated for the same subgroups, excluding patients 
with a converted laparoscopic resection. The influence of laparoscopic 
resection on different postoperative complications that may contribute 
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to the risk of postoperative mortality were evaluated using both 
univariable and multivariable analysis. The significance level of 
univariable analysis was set at a two-tailed p-value of 0.05, but factors 
were entered in the multivariable analysis at a p-value of less than 
0.10 using an ENTER model. The following factors were included in 
multivariable analysis to adjust for differences in casemix between OR 
and LR; sex, age, ASA classification, BMI, previous abdominal surgery, 
emergency surgery, additional resection for locally advanced/metastatic 
disease, pT-classification, and metastatic disease. No process or 
treatment characteristics were included in the multivariable analysis for 
risk-adjustment. Statistical analyses were performed in PASW Statistics, 
version 20 (SPSS inc., Chicago, IL).
RESULTS
Patients and hospitals
A total of 35,714 patients, registered by 92 hospitals, met the inclusion 
criteria. Annual laparoscopic resection rates at hospital level were 
calculated. This showed hospitals still performing laparoscopic 
resection on an incidental basis, hospitals with laparoscopic resection 
being already fully implemented at the start of the study period, 
and in between several stable, increasing or decreasing levels of 
application of laparoscopic resection. The overall laparoscopic resection 
rate increased from 37 percent in 2010 to 58 percent in 2013. The 
percentage of converted laparoscopic resections decreased from 13.6 
percent in 2010 to 13.3 percent in 2013. Categorization by the rate of 
laparoscopic resection per hospital resulted in 29 low-rate laparoscopic 
resection (LRL) hospitals, 46 medium-rate laparoscopic resection (MRL) 
and 17 high-rate laparoscopic resection (HRL) hospitals, in which 
11,579, 18,191 and 5,944 patients were treated, respectively. Table 1 
shows the distribution of casemix factors among LRL, MRL and HRL 
hospitals. Patient characteristics were similar among the three types 
of hospitals, but LRL hospitals treated up to 5 percent more patients 
with locally advanced disease and up to 4.5 percent more patients with 
metastatic disease compared to MRL and HRL hospitals. 
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Risk stratified comparison of postoperative mortality
The overall percentage of postoperative mortality for this study period 
was 3.3 percent; 3.9 percent for patients with colon carcinoma and 2.0 
percent for patients with rectal carcinoma. 
Emergency surgery, T4 stage and M1 stage were excluded for the 
purpose of the primary analysis of postoperative mortality after 
laparoscopic and open approach, based on the observed casemix 
differences among the three hospital categories and the generally 
considered relative contraindications for a laparoscopic approach. 
Within the total group of patients undergoing elective surgery for non-
locally advanced, non-metastasized colorectal cancer (T1-3N0-2M0 
stage), 22 different subgroups were defined based on age (<70, ≥70 and 
≥80 years), ASA score (1-2 and 3-4), and previous abdominal surgery. 
Postoperative mortality was lower after LR compared to OR in all 22 
subgroups after elective resection of T1-3N0-2M0 colon cancer (Table 
2), with an absolute risk reduction ranging from 0.4% (<70 years, 
ASA 1-2) to 4.6% (≥80 years, ASA 3-4). The lower relative risk of 
postoperative mortality after LR was statistically significant in 20 of 
22 subgroups, with a range between 0.18 (95% confidence interval (CI) 
0.05-0.66) and 0.64 (95% CI 0.45-0.90). After elective surgery for T1-
3N0-2M0 rectal cancer, postoperative mortality differed significantly 
in 4 of 22 subgroups. In patients of 70 years and older, with or without 
previous abdominal surgery, LR resulted in an absolute risk reduction 
of mortality of 1.8 and 2.4 percent and a relative risk of 0.58 (95% CI 
0.41-0.82) and 0.53 (95% CI 0.35-0.81), respectively. The other two 
subgroups consisted of patients of 70 years and older, and ASA 3-4 with 
or without previous abdominal surgery: absolute risk reduction of 4.0 
and 4.7 percent and relative risk of 0.57 (95% CI 0.35-0.92) and 0.56 
(95% CI 0.32-0.98), respectively. 
Emergency surgery and advanced disease were analyzed in a secondary 
analysis with a relatively high risk of bias. Significantly different 
mortality rates were found for elective colon surgery for T4 stage and 
emergency colonic surgery, with or without previous abdominal surgery, 
in favor of LR (Table 2).  
The analysis was repeated for all the above-mentioned subgroups 
excluding patients with a converted laparoscopic resection. This showed 
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nearly equal results, with an equal amount of subgroups in which 
laparoscopic resection led to a significantly lowered percentage of 
postoperative mortality (data not shown). 
Surgical approach and postoperative complications
Table 3 shows the surgical and non-surgical postoperative complication 
rates after OR and LR. In univariable analysis, surgical complications 
and any type of non-surgical complications were significantly higher 
in the OR group. Multivariable analysis showed an OR of 0.66 (95% CI 
0.63 – 0.70) for overall postoperative complications in favor of LR. A 
laparoscopic approach was also independently associated with a lower 
risk of surgical complications (OR 0.88; 95% CI 0.83 – 0.94), pulmonary 
complications (OR 0.73; 95% CI 0.66 – 082), cardiac complications (OR 
0.73; 95% CI 0.64 – 0.84), infectious complications (OR 0.74; 95% CI 
0.66 – 0.84), and other complications (OR 0.72; 95% CI 0.65 – 0.79). 
DISCUSSION
This population-based study demonstrates the significantly reduced 
risk of postoperative mortality after laparoscopic resection compared 
to open surgery in patients with non-locally advanced, non-metastatic 
colon cancer in an elective setting. The relative risk reduction was 
approximately 50% for all risk categories, but this translated into an 
absolute lower mortality rate of 0.4 percent in a priori low risk patients 
(<70 years, ASA 1-2) and 4.6 percent in a priori high risk patients (≥80 
years, ASA 3-4). These observations were similar in rectal cancer, but 
differences in mortality were less often statistically significant due 
to lower numbers of patients and events. In contrast to what is often 
believed, our data shows that especially high-risk patients benefit from 
laparoscopic surgery. The present finding of a significant reduction of 
non-surgical complications associated with laparoscopic surgery, e.g. 
cardiopulmonary complications, demonstrates the clinical implications 
of reduced surgical stress response that becomes most apparent in the 
elderly frail patients. 
The effect of laparoscopic surgery on postoperative mortality has been 
studied previously. Meta-analyses of RCTs showed a trend towards 
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lower postoperative mortality for laparoscopic resection compared 
to an open approach. The recently updated Cochrane analysis showed 
a relative risk of 0.81 in favor of laparoscopic resection, but with 
a wide confidence interval (95% CI 0.50-1.32).17 A meta-analysis 
published in 2012 included 3 RCTs in ERAS setting and showed an 
OR for postoperative mortality of 0.33 (95% CI 0.09-1.18) in favor 
of laparoscopic resection.7 All these meta-analyses, however, lacked 
sufficient power to demonstrate a significant relationship between 
laparoscopic surgery and lowered postoperative mortality in the 
relatively healthy study populations that were included in the  
individual trials.  
Population studies on the subject are able to include higher numbers 
of patients from daily clinical practice with different operative risk 
levels, compared to RCTs with strict selection criteria. In 2012, we 
reported a lower casemix corrected mortality rate after laparoscopic 
surgery compared to open resection (2.4% versus 4.0%; OR 0.63; 
P<0.01) based on all patients registered in the DSCA in 2010.12 Other 
population studies have confirmed these findings.9-11 The question 
remained to what extend the results of these analyses were subject to 
selection bias and which specific patient groups would benefit most 
from a minimally invasive approach. While casemix correction reduces 
the effect of confounding factors, it is not likely that a multivariable 
model in a heterogeneous population will sufficiently correct for the 
whole range of factors that may influence the decision to perform open 
or laparoscopic surgery. To deal with these inherent methodological 
problems of non-randomized comparisons in a different way, we tried 
to gain more insight by using a risk-stratified comparison between 
relatively homogenous subgroups. Analysis of the laparoscopic resection 
rate at hospital level revealed that selection bias was most likely related 
to advanced disease while the other casemix factors were remarkably 
comparable among the low, medium and high laparoscopy hospitals. 
Apparently, low and high laparoscopy hospitals are treating similar 
patients, except for a small subgroup. This led us to conclude that the 
decision on the surgical approach in non-metastatic localized colorectal 
cancer seems to be hospital driven, depending on the availability of 
adequate equipment and surgeons experienced in the technique. Based 
on this conclusion, one may also hypothesize that better results after 
a laparoscopic approach are not only explained by the technique itself, 
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but also by the quality of the surgeons and hospital setting. However, it 
is difficult to prove that laparoscopy is performed by ‘better’ surgeons 
in ‘better’ hospitals.
Although a RCT is considered to provide the highest level of evidence, 
its restrictions become more and more apparent. National health 
registries are a unique source of data, due to the absence of preselected 
populations and large numbers of patients. In this way, research 
questions that are unlikely to be answered in RCTs can be analyzed 
with high external validity because it reflects daily clinical practice. 
The comparison between laparoscopic and open surgery for colorectal 
carcinoma is a good example of its usage.
The largest reduction in absolute mortality rate by the use of 
laparoscopic surgery was found in subgroups comprising high-
risk patients. The reduction of the surgical stress response caused 
by laparoscopic surgery could, theoretically speaking, lead to the 
reduction of postoperative complications. A pooled analysis of 11 
studies, analyzing the use of laparoscopic resection in an elderly 
population, showed a significant difference in pulmonary and cardiac 
complications.18 Elderly patients who underwent open surgery 
showed a doubled rate of cardiopulmonary complications compared 
to patients of similar age who underwent laparoscopic resection. 
Initially, elderly patients with increased cardiopulmonary risk were 
considered a contraindication for a laparoscopic approach, because 
of high intra-abdominal pressure and extreme Trendelenburg 
positioning during laparoscopic surgery with negative impact on 
ventilation and hemodynamics related to reduced venous return.19 
However, the postoperative risk of open surgery with a higher stress 
response and pain might be more likely to influence the outcome 
rather than the intra-operative risk which can often be adequately 
managed during anesthesia. Support for this mechanism is found in 
the Dutch LAFA study which describes the inflammatory response in 
four study arms; laparoscopic or open resection with or without ERAS 
perioperative care.20 Human Leukocyte Antigen (HLA-DR) expression, 
indicating immune competence, showed the highest levels in patients 
undergoing a laparoscopic resection with ERAS care. Interleukin 6 
(IL-6), indicating inflammatory response, showed the highest levels 
in patients undergoing an open procedure without ERAS.21 Wang et al. 
confirmed this finding in 2012.22 The relationship between the systemic 
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inflammatory response after surgery and the prognosis of the patient 
has been widely studied in oncologic surgery. The validated Glasgow 
prognostic score, consisting of preoperative CRP and albumin has an 
independently predicting value for cancer specific survival.23, 24 In the 
light of the lowered postoperative inflammatory response caused by 
laparoscopic surgery, minimal invasive surgery could be of positive 
effect on cancer specific survival as well, although long-term results of 
RCTs do not support this. 
Limitations of the present population bases analysis are the 
methodological issues related to a non-randomized comparison with 
risk of selection bias, as already mentioned. Differences in postoperative 
care among the hospitals may have contributed to the present findings, 
although recent meta-analyses showed that ERAS has no impact 
on postoperative mortality and that laparoscopy has independent 
advantages beyond ERAS care.25, 26 Furthermore, the DSCA only provides 
30-day and in-hospital mortality rates, while 90-day or even 1-year 
mortality rates may be more appropriate, especially in the elderly frail 
patients. In the near future, we plan to match the two databases of the 
DSCA and national cancer registry at an individual patient level, which 
enables similar analyses on long-term outcome. 
In conclusion, this population-based analysis demonstrates a reduced 
mortality risk after elective minimally invasive surgery for localized 
colorectal cancer compared to an open approach, especially in a 
priori high-risk patients. The implication of these findings are further 
implementation of laparoscopic colorectal surgery by facilitating 
adequate training of colorectal surgeons and providing an adequate 
infrastructure in hospitals and countries in which open surgery is still 
standard of care.
Acknowledgment: The authors would like to thank all surgeons, 
registrars, physician assistants and administrative nurses that 
registered all the patients in the DSCA, as well as the Dutch Surgical 
Colorectal Audit group. 
116
REFERENCES
1. Ohtani H, Tamamori Y, 
Arimoto Y, et al. A meta-analysis 
of the short- and long-term 
results of randomized controlled 
trials that compared laparoscopy-
assisted and open colectomy 
for colon cancer. J Cancer 2012; 
3:49-57.
2. Trastulli S, Cirocchi R, 
Listorti C, et al. Laparoscopic vs 
open resection for rectal cancer: 
a meta-analysis of randomized 
clinical trials. Colorectal Dis 
2012; 14:e277-96.
3. Taylor GW, Jayne DG, 
Brown SR, et al. Adhesions and 
incisional hernias following 
laparoscopic versus open surgery 
for colorectal cancer in the 
CLASICC trial. Br J Surg 2010; 
97:70-8.
4. Burns EM, Currie A, 
Bottle A, et al. Minimal-access 
colorectal surgery is associated 
with fewer adhesion-related 
admissions than open surgery. Br 
J Surg 2013; 100:152-9.
5. Bartels SA, Vlug MS, 
Hollmann MW, et al. Small bowel 
obstruction, incisional hernia 
and survival after laparoscopic 
and open colonic resection (LAFA 
study). Br J Surg 2014; 101:1153-
9.
6. Keller DS, Champagne 
BJ, Reynolds HL, Jr., et al. Cost-
effectiveness of laparoscopy in 
rectal cancer. Dis Colon Rectum 
2014; 57:564-9.
7. Li MZ, Xiao LB, Wu 
WH, et al. Meta-analysis of 
laparoscopic versus open 
colorectal surgery within fast-
track perioperative care. Dis 
Colon Rectum 2012; 55:821-7.
8. Breukink S, Pierie J, 
Wiggers T. Laparoscopic versus 
open total mesorectal excision for 
rectal cancer. Cochrane Database 
Syst Rev 2006:CD005200.
9. Byrne BE, Mamidanna 
R, Vincent CA, et al. Population-
based cohort study comparing 
30- and 90-day institutional 
mortality rates after colorectal 
surgery. Br J Surg 2013; 
100:1810-7.
10. Panis Y, Maggiori L, 
Caranhac G, et al. Mortality 
after colorectal cancer surgery: 
a French survey of more than 
84,000 patients. Ann Surg 2011; 
254:738-43; discussion 743-4.
11. Faiz O, Haji A, Bottle A, 
et al. Elective colonic surgery 
for cancer in the elderly: an 
investigation into postoperative 
mortality in English NHS 
hospitals between 1996 and 




12. Kolfschoten NE, van 
Leersum NJ, Gooiker GA, et al. 
Successful and safe introduction 
of laparoscopic colorectal cancer 
surgery in Dutch hospitals. Ann 
Surg 2013; 257:916-21.
13. Van Leersum NJ, Snijders 
HS, Henneman D, et al. The Dutch 
surgical colorectal audit. Eur J 
Surg Oncol 2013; 39:1063-70.
14. Dutch Institute for 
Clinical Auditing. Annual Reports 
2012. http://www.clinicalaudit.
nl. 
15. Kolfschoten NE, Marang 
van de Mheen PJ, Gooiker GA, 
et al. Variation in casemix 
between hospitals treating 
colorectal cancer patients in the 
Netherlands. Eur J Surg Oncol 
2011; 37:956-63.
16. van Leersum NJ, 
Aalbers AG, Snijders HS, et 
al. Synchronous colorectal 
carcinoma: a risk factor in 
colorectal cancer surgery. Dis 
Colon Rectum 2014; 57:460-6.
17. Vennix S, Pelzers L, 
Bouvy N, et al. Laparoscopic 
versus open total mesorectal 
excision for rectal cancer. 
Cochrane Database Syst Rev 2014; 
4:CD005200.
18. Grailey K, Markar 
SR, Karthikesalingam A, et 
al. Laparoscopic versus open 
colorectal resection in the elderly 
population. Surg Endosc 2013; 
27:19-30.
19. Weber DM. Laparoscopic 
surgery: an excellent approach in 
elderly patients. Arch Surg 2003; 
138:1083-8.
20. Vlug MS, Wind J, 
Hollmann MW, et al. Laparoscopy 
in combination with fast track 
multimodal management is the 
best perioperative strategy in 
patients undergoing colonic 
surgery: a randomized clinical 
trial (LAFA-study). Ann Surg 
2011; 254:868-75.
21. Veenhof AA, Vlug 
MS, van der Pas MH, et al. 
Surgical stress response and 
postoperative immune function 
after laparoscopy or open surgery 
with fast track or standard 
perioperative care: a randomized 
trial. Ann Surg 2012; 255:216-21.
22. Wang G, Jiang Z, Zhao 
K, et al. Immunologic response 
after laparoscopic colon cancer 
operation within an enhanced 
recovery program. J Gastrointest 
Surg 2012; 16:1379-88.
118
23. Guthrie GJ, Roxburgh 
CS, Farhan-Alanie OM, et al. 
Comparison of the prognostic 
value of longitudinal 
measurements of systemic 
inflammation in patients 
undergoing curative resection 
of colorectal cancer. Br J Cancer 
2013; 109:24-8.
24. Guthrie GJ, Roxburgh 
CS, Richards CH, et al. Circulating 
IL-6 concentrations link tumor 
necrosis and systemic and local 
inflammatory responses in 
patients undergoing resection 
for colorectal cancer. Br J Cancer 
2013; 109:131-7.
25. Lv L, Shao YF, Zhou YB. 
The enhanced recovery after 
surgery (ERAS) pathway for 
patients undergoing colorectal 
surgery: an update of meta-
analysis of randomized controlled 
trials. Int J Colorectal Dis 2012; 
27:1549-54.
26. Spanjersberg WR, van 
Sambeeck JD, Bremers A, et al. 
Systematic review and meta-
analysis for laparoscopic versus 
open colon surgery with or 




















































































































































































































































































































































































































































































































































































































































































































    











































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































)     
























































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































   
   
   
   
   
   
   
   
   

















































































































































































































































































































































QUALITY OF LAPAROSCOPIC RECTAL CANCER RESECTION 
IN THE NETHERLANDS, A DECADE FROM START OF THE 
COLOR II TRIAL; A MATCHED COHORT STUDY. 
Lieke Gietelink, Charlotte L. Deijen, Jurriaan B. Tuynman, Susan van 
Dieren, Willem A. Bemelman, Michel W.J.M. Wouters, Jaap H. Bonjer 




Background: Laparoscopic surgery for rectal cancer has become 
routine practice in the Netherlands 10 years after initiation of 
the COLOR II trial. As rectal cancer surgery evolved, one might 
question whether this trial is still representative for current national 
performance. Therefore, this study aimed to compare recent DCRA data 
with the COLOR II trial, using circumferential resection margin (CRM) as 
main quality indicator.14 
Methods: All Dutch patients included in the laparoscopic arm of the 
COLOR II trial were matched (1:2) to patients registered in the DCRA 
after laparoscopic resection for primary rectal cancer (2013- 2014) on 
the variables; sex, age, tumor distance from anal verge, pT-classification, 
ASA physical status, and type of operation. 
Results: A total of 103 Dutch patients were selected from the COLOR II 
trial, and matched with 206 patients from the DCRA. The percentage of 
involved CRM was 3.4% in the DCRA patients, which was significantly 
lower compared to 10.7% in the Dutch COLOR II patients (P=0.018). 
Conversion rate was significantly lower in the DCRA compared to 
the COLOR II trial: 9% vs. 18% (P=0.049). The DCRA group had a 
significantly higher mean number of examined lymph nodes (11.6 
vs. 13.8; P=0.038) and a lower median postoperative hospital stay (7 
vs. 8 days; P=0.007). Postoperative complication, reintervention and 
mortality rates were not significantly different.
Conclusion: Routine implementation of laparoscopic surgery for rectal 
cancer in the Netherlands after the COLOR II trial was accompanied by 
substantially lower CRM positivity rates, besides lower conversion rates 
and shorter hospital stay. This study shows that the rapid evolution 
in rectal cancer management over time requires real-time data and 




Laparoscopic surgery for colorectal cancer started in the early 1990s 
and evolved to routine practice in several institutes worldwide over 
the last decades.1 There were concerns on the oncological quality 
of the resection with early reports of port-site tumor metastases.2, 3 
Early conducted trials mainly included patients with colon cancer and 
demonstrated improved postoperative recovery while maintaining 
comparable oncologic outcomes for laparoscopic surgery (LS) compared 
to open surgery (OS).4-7 
Further research was needed to evaluate whether these outcomes 
could also be achieved for the technically more challenging resection 
of rectal cancer. The COlorectal cancer Laparoscopic or Open Resection 
(COLOR II) trial included 1044 patients and showed similar short-
term benefits of LS as were seen in colon cancer. In 2015, the COLOR 
II study group published the long-term outcomes and reported that LS 
results in comparable survival and recurrence rates as OS at 3 years 
postoperative.8, 9 
LS for rectal cancer has been rapidly and safely implemented in the 
Netherlands and has become routine practice in most recent years  
based on data from the Dutch ColoRectal Audit (DCRA),  the former 
DSCA.10, 11 It has been over 10 years that the COLOR II trial was initiated 
and the results of this trial, amongst others, are commonly quoted. As 
LS has a steep learning curve and rectal cancer surgery is presently 
concentrated with a minimal hospital volume of 20, one might question 
whether the COLOR II data are still representative for current national 
performance. Furthermore, two recent trials again raised questions 
about the quality of the oncological resection of LS for rectal cancer.12, 
13 Therefore, this study aims to analyse current oncological quality of LS 
for rectal cancer by matched comparison of data from the DCRA and the 




For the purpose of this matched comparative cohort study, all Dutch 
patients included in the laparoscopic arm of the COLOR II trial between 
2004 and 2010 were selected from the original database. All patients 
registered in the DCRA after laparoscopic resection for primary rectal 
cancer between January 1st 2013 and December 31th, 2014, were eligible 
matches. Patients with an unreported CRM and those with a complete 
pathological response after preoperative radiotherapy were excluded 
from analyses. Furthermore, exclusion criteria of the COLOR II trial were 
also applied to the DCRA population, and registered local excision or 
emergency procedures in the DCRA were also excluded.
The primary outcome parameter was CRM involvement. CRM 
involvement was defined as CRM < 2 mm in the COLOR II trial and as 
CRM ≤ 1 mm in the DCRA which is according to the definition of the 
current Dutch colorectal cancer guideline.15  Secondary outcomes 
were conversion to open surgery, lymph node retrieval, postoperative 
complications (in specific anastomotic leakage and cardiopulmonary 
complications), reintervention, length of hospital stay, and mortality. 
Anastomotic leakage was defined as leakage leading to a reintervention. 
Postoperative complications and mortality were registered within 
28 and 30 days postoperatively in the COLOR II trial and DCRA, 
respectively, or within the period of admission following the resection.
COLOR II trial
The COLOR II trial was a non-inferiority phase 3 trial randomizing 
patients with non-metastatic, non-locally advanced rectal cancer 
between laparoscopic and open surgery in a 2:1 ratio. Exclusion 
criteria were: age <18 years, distance from tumor to anal verge > 15cm, 
metastatic disease, tumor histologically not proven adenocarcinoma, 
T1 tumors eligible for local excision, T4 tumors, T3 tumors with 
a threatened circumferential margin (distance < 2 mm), signs of 
obstruction, patients categorised as ASA (American Society of 
Anesthesiologists) classification > III and planned simultaneuous 
colorectal surgery. The primary outcome was locoregional recurrence at 




Data for the matched cohort were derived from the DCRA, a disease 
specific national audit. This audit collects information on patient, tumor, 
treatment and outcome characteristics and containes approximately 97 
percent of all patients with a resection for primary colorectal carcinoma 
in the Netherlands.16 Details of this dataset regarding data collection 
and methodology have been published previously.17, 18 
Statistical analyses
Dutch patients included in the COLOR II trial that were randomised 
in the laparoscopic group were matched to patients who underwent 
laparoscopic surgery in the DCRA on a 1:2 ratio on the following 
variables; sex, age (continuous; years), distance tumor-anus 
(continuous; cm), pathological T classification, ASA physical status (I/
II/III) and type of operation (simplified to APR/no APR). A predefined 
maximal deviation (fuzz factor) was set: sex, identical; age, ±10 years; 
distance tumor to anal verge, ±5 cm; pathological T-classification, 
identical; ASA physical status, identical; type of operation, identical. For 
every case, the most homologous control was chosen. Patients from the 
COLOR II with missing data of matching variables were matched on the 
remaining variables.
Differences in baseline characteristics between the two cohorts were 
analysed with paired analyses. Categorical variables were compared 
using a conditional logistic regression analysis (Wald test). Continuous 
variables, both normally and not normally distributed, were compared 
using a general linear model (F-test). Outcomes were compared between 
COLOR II and DCRA with the previously mentioned statistical tests. 
A p-value of less than 0.05 was considered statistically significant. 
Statistical analyses were performed in SPSS and R. 
Ethical approval and informed consent
For this study, no ethical approval or informed consent was required 
according to national  legislation.
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RESULTS
A total of 103 patients were selected from the COLOR II trial and 
matched with 206 patients of the DCRA. Table 1 shows the baseline 
characteristics of patients included in the COLOR II trial and DCRA after 
matching in a 1;2 ratio. Eighty percent of the patients included in the 
COLOR II population underwent a form of preoperative radiotherapy 
compared to 74 percent in the DCRA population. After matching for 
APR/no APR, a higher percentage of patients in the DCRA received a 
low anterior resection with diverting stoma or Hartmann’s procedure 
compared to the Dutch COLOR II patients. The conversion rate was 
significantly lower in the DCRA group: 9.2% vs. 17.5% (p=0.049).
Tabel 2 shows the pathological outcomes of the matched pair analysis. The 
pathological N classification was not significantly different between the 
groups (p=0.549). CRM involvement was 10.7% in the COLOR II trial and 
3.4% in the DCRA matched cohort (p=0.018). The number of examined 
lymph nodes was significantly higher in the DCRA cohort compared to 
the COLOR II patients: 13.8 vs 11.6 (p=0.038). The median postoperative 
hospital stay was one day shorter in the DRCA population (p=0.007). 
Other postoperative outcomes did not show significant differences 
between the two populations. Table 3 shows the postoperative outcomes 
of the COLOR II and DCRA population. 
DISCUSSION
This matched cohort study demonstrates that the oncological quality 
of laparoscopic surgery for rectal cancer in the Netherlands has 
been improved over the last decade. The percentage of patients with 
an involved CRM was significantly lower in the DCRA population 
(2013-2014) compared to the Dutch COLOR II patients (2004-2010). 
Furthermore, other improvements have been achieved within a ten-
year period in which laparoscopic resection became part of routine 
daily practice, as reflected by lower conversion rate and one day 
shorter hospital stay. Our study shows the time related development 
of laparoscopic rectal cancer surgery and the implementation of the 




Laparoscopic surgery for rectal cancer was quickly implemented in 
rectal cancer care in the Netherlands. At the time the COLOR II trial 
complete accrual in 2010, 37% of rectal cancer resections were already 
performed laparoscopically. This percentage was high compared to 
other countries and accompanied by a relatively low conversion rate 
(13%).19 The percentage of laparoscopic rectal cancer resections in 
the Netherlands increased in recent years to 83% in 2015, which is 
still high compared to surrounding countries.20, 21 As multiple studies 
found a relationship between surgical experience with laparoscopic 
colorectal resection and improving outcomes, both intraoperative 
and postoperative, a specific time driven influence on the quality of 
laparoscopic resections in the Netherlands can thus be expected after a 
decade of experience.25 The relatively low conversion rate in the DCRA 
population in our matched analysis (9.2%) combined with the high 
percentage of rectal cancer patients undergoing laparoscopic surgery in 
the Netherlands overall is a clear example of this learning curve.4  
Other changes in colorectal cancer care have positively influenced the 
outcomes for patients with colorectal cancer.18 The implementation 
of Enhanced Recovery After Surgery (ERAS) care, which involves a 
small surgical incision, adequate pain management, short period of 
immobility, and quick return to normal diet, has gained ground and 
shows positive results for both open and laparoscopic surgery.31 
Centralisation of the technically more challenging resection of rectal 
cancer was stimulated by evidence of a relationship between volume 
and quality of colorectal cancer surgery.22-24 In the Netherlands this 
has led to the introduction of a mandatory annual volume of 20 
rectal cancer resections per hospital, as stated by the Dutch Society 
of Surgery. Together with a larger volume per surgeon leading to 
more experience, it is generally believed that volume is to be seen 
as a ‘proxy’ for other important structural and process factors in the 
chain of multidisciplinary treatment.23, 24 Laparoscopy encouraged the 
formation of subspecialized colorectal surgeons in order to gain specific 
experience. This could have further enhanced quality improvement in 
both expert and non-expert centres, explaining the overall improvement 
at a population level. It has been shown that such specialization 
ultimately translates into better survival of colorectal cancer patients.26 
Therefore, the current matched comparison illustrates both influences 
of time related development of a surgical technique and adhering 
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processes and structure as well as implementation of the technique in 
non-expert centres.
Our study has some limitations. We decided to include only the 
Dutch patients from the COLOR II trial, for which reason the number 
of matched patients was relatively low with less statistical power. 
Nevertheless, we think that this study gives a good overview on how far 
laparoscopic surgery has advanced and that renowned quoted studies 
show different results compared to more recent data. Furthermore, 
we only recently added the variable ‘macroscopic completeness of the 
TME specimen’ to the DCRA dataset, another important item of quality 
of rectal cancer surgery. Therefore this variable was not available for 
our study population. The COLOR II study defined involvement of CRM 
as tumor cells within 2mm (<2mm) between the outermost part of the 
tumor and the CRM, whereas the DCRA regards the CRM involved if the 
tumor-free margin is 1 mm or less (≤1mm). This discrepancy benefits 
the result of the DSCA population. However as CRM is usually not 
measured/registered in decimals, the difference should be small and 
does not undermine the conclusion of this study. 
In conclusion, this study shows that laparoscopic surgery in patients 
with rectal cancer in the Netherlands has evolved and improved over 
the years, implicating that laparoscopic surgery has been successfully 
implemented in the Netherlands. The percentage of patients with an 
involved CRM was significantly lower in the DCRA population compared 
to the COLOR II population. This study shows once again the value of 
national audits because they are able to provide us with real-time data 
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ABSTRACT
Background: The aim of this study was to evaluate current clinical 
practice and treatment outcomes regarding locally advanced colon 
cancer (LACC) at population level. 
Patients/Methods: Data from the Dutch Surgical Colorectal Audit 
(DSCA) from 2009 to 2014 were used. A total of 34,527 patients 
underwent resection for non-LACC and 6,918 for LACC. The latter was 
defined as cT4 and/or pT4 stage. LACC was divided into those with 
multivisceral resection (LACC-MV (n=3,385)) and without  (LACC-noMV 
(n=1,595)). Guideline adherence, treatment strategy, and short term 
outcomes were evaluated.  
Results: Guideline adherence regarding preoperative imaging was 
more than 90% and 80% regarding preoperative multidisciplinary team 
discussion. In the elective setting, neoadjuvant (chemo)radiotherapy 
was applied in 6.2% of the cT4 cases and neoadjuvant chemotherapy in 
4.0%. R0 resection rates were 99%, 91% and 87% in non-LACC, LACC-
noMV and LACC-MV patients, respectively (p<0.001). A postoperative 
complicated course occurred in 17%, 25% and 29% (p<0.001), and the 
30 day/in-hospital mortality was 3.6%, 6.0%, and 5.4% (p<0.001) in the 
non-LACC, LACC-noMV and LACC-MV groups, respectively. 
Discussion/Conclusion: This population based study suggests that 
there is room for improvement in the treatment of LACC, with regard 
to short term surgical outcomes as well as oncological outcomes, 
i.e. radicality of resection. Improvement might be expected from 
optimized preoperative imaging, routine MDT discussions, and further 
specialisation and centralisation of care. Optimized use of neoadjuvant 
treatment strategies based on already available and upcoming evidence 
is likely to result in a better margin status and related to that a 
better long-term prognosis. Furthermore, lower R0 resection rates in 
emergency setting suggest a potential role for bridging strategies in 
order to enable optimal staging, neoadjuvant treatment and elective 




Colon cancer is highly prevalent world-wide and a major public health 
problem.1 A substantial group of patients (10-15%) presents with 
locally advanced colon cancer (LACC), which has an important impact 
on the management and prognosis of the disease.The standard curative 
intent treatment of LACC is a complete resection of the tumor (R0 
resection) followed by adjuvant systemic chemotherapy depending on 
the age and clinical condition of the patient.2,3
LACC can be subdivided into T4a stage with serosal ingrowth and T4b 
stage with ingrowth into nearby tissues or organs (TNM, 7th edition). 
In order to achieve a R0 resection of the latter tumors, the surgical 
approach should include a multivisceral resection with or without 
neoadjuvant down staging.4,5 Despite the prevalence of LACC and the 
relatively poor prognosis, treatment of LACC is still an underexposed 
area in the field of colorectal cancer care when compared to, for 
example, the extensive literature on locally advanced rectal cancer. 
The Dutch Surgical Colorectal Audit (DSCA) has been evaluating and 
reporting on the quality of care of primary colorectal cancer surgery 
since 2009.6,7 The aim of this study was to evaluate current clinical 
practice regarding short-term outcomes of the treatment of LACC at 




Data were derived from the DSCA, a disease specific national audit. The 
audit collects information on patient, tumor, treatment characteristics 
and outcomes and contains data from approximately 97 percent of all 
patients who underwent a resection for primary colorectal cancer in the 
Netherlands. Data-entry is obligatory and data are stored in a  
highly secured online database. All 92 Dutch hospitals participate and 
appoint a surgeon who is responsible for data-entry. The dataset is 
cross-checked several times with data registered in the Netherlands 
Cancer Registry (NCR) to ensure completeness. Detailed information 
on the validity, collection and methodology of the dataset has been 
published previously.6,7
Patients
For this study, no ethical approval or informed consent was required 
under Dutch law. All patients who underwent surgery between January 
1st 2009 and December 31st 2014 and were registered before March 
15, 2015, were evaluated. Patients with multiple synchronous tumors 
within the colon were included, but patients with a second tumor in the 
rectum were excluded. Patients were considered eligible for this study 
if at least the following data were available: location of the tumor, date 
of surgery and survival status at the time of hospital discharge. Based 
on these criteria, 98.7 percent (n=39,491) of all registered patients 
were available for analysis. Furthermore, for the purpose of the present 
analysis, all patients with metastatic disease were excluded. 
Definitions
In the DSCA, both clinical and pathological T stage were available, but 
without subdivision in T4a and T4b. LACC was defined as all patients 
with a registered clinical and/or pathological T4 stage. The extent 
of surgery for the primary tumor was registered in the DSCA as no, 
limited or extensive additional resections for local ingrowth. Limited 
additional resections were defined as resections of the abdominal 
wall, the omentum or the ovaries. Extensive additional resections 
referred to resections of the pancreas, spleen, kidney, liver, stomach, 
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bladder, ureters, uterus or additional bowel resections. The organs 
involved or the exact locations of the additional resections are not 
specified.  The variable “additional resections for local ingrowth” was 
used to define two subgroups: LACC without additional/multivisceral 
resections (LACC-noMV) and LACC with limited or extended additional/
multivisceral resections (LACC-MV). All other colon cancer resections 
were referred to as non-LACC. In short, the following three subgroups 
were used in this study: LACC-noMV: patients who underwent a 
resection of a cT4 and/or pT4 colon carcinoma without the need 
for a multivisceral resection; LACC-MV: patients who underwent a 
multivisceral resection of a cT4 and/or pT4 colon carcinoma; Non-LACC: 
patients who underwent a resection for a T1-3 colon cancer (i.e. a tumor 
that was not classified as either cT4 or pT4). 
Emergency surgery was defined as surgery performed within 12 hours 
after the procedure was scheduled. Urgent surgery referred to semi-
urgent procedures that were scheduled more than 12 hours before being 
performed, but outside of the elective program. Surgical approach was 
either open, laparoscopic or converted laparoscopic surgery. Hospital 
volume was defined as the number of resections performed for LACC-MV 
per hospital per year. 
The outcome variables were guideline adherence (see below for the 
guidelines), radicality of resection and postoperative course. The 
subcategories for radicality of resections were: R0: complete tumor 
resection with all margins histologically uninvolved; R1: incomplete 
resection with microscopic surgical resection margin involvement; R2: 
incomplete tumor resection with gross residual tumor that was not 
resected. A complicated course referred to a postoperative complication 
leading to a re-intervention, hospital stay longer than 14 days, or 
death. Surgical complications were complications directly related to the 
surgical procedure (i.e. anastomotic leakage, abscess, bleeding, ileus). 
Non-surgical complications were not directly related to the surgery 
(i.e. postoperative pneumonia). Mortality was defined as 30 day or in-
hospital mortality. 
Treatment for LACC according to the Dutch guidelines
The Dutch colorectal guideline used until June 2014 advised to 
routinely perform a preoperative CT scan for colon cancer. In case 
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of LACC, this was aimed at optimizing the surgical approach with 
‘en bloc’ multivisceral resection and at considering neoadjuvant 
therapy.  Preoperative (chemo)radiotherapy had to be considered if 
R0 resection was not found to be achievable based on CT imaging or 
intraoperative findings from explorative laparotomy. Postoperative 
(chemo)radiotherapy had to be considered in cases of R2 resection with 
clipping of the operative field. In the revised guideline of June 2014 
(www.oncoline.nl), preoperative imaging as well as multidisciplinary 
team (MDT) discussion was recommended in order to select the 
optimal treatment strategy. Preoperative systemic therapy is added 
as a neoadjuvant treatment option, besides (chemo)radiotherapy. 
Postoperative (chemo)radiotherapy for LACC is no longer advised. 
Statistical analysis
Differences in baseline characteristics and outcome variables between 
patients with non-LACC, LACC-noMV and LACC-MV were analyzed using a 
Chi square test or Fisher’s exact test in the case of categorical variables. 
The Kruskal-Wallis one-way analysis of variance was used for continues 
(nonparametric) variables. R0 resection proportions were compared 
between different subgroups based on the type of resection, surgical 
approach, neo-adjuvant treatment and hospital volume. To determine 
potential improvement in quality of care over time, outcome parameters 
were plotted against year of registration. The trend over time was 
analyzed using the Chi square for linearity. A p-value of less than 
0.05 was considered statistically significant. Statistical analyses were 
performed in PASW Statistics, version 22 (SPSS inc., Chicago, IL).
RESULTS
Patients 
Of all colon cancer patients registered between the 1st of January 2009 
and the 31st of December 2014 in 92 Dutch hospitals, 39,491 were 
eligible for analysis. A total of 4,964 patients were staged as M1 and 
excluded from this analysis. Clinical T stage was known in only 27% 
of the remaining 34,527 patients and cT4 stage was registered in 578 
patients. A total of 4730 patients had a pathological T4 tumor. There 
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was an overlap between these two groups in the case of 328 patients 
who had both a cT4 and pT4 classified tumor. This resulted in a total of 
4,980 patients with a cT4 and/or pT4 stage (LACC) and the remaining 
29,547 (86%) were non-LACC patients (figure 1). In the LACC group, 
3,385 patients (68%) were classified as LACC-noMV and 1,595 patients 
(32%) as LACC-MV. Limited and extensive additional resections were 
performed in 53% and 47% of the LACC-MV patients, respectively. 
Baseline characteristics and surgery
Baseline characteristics of the three subgroups are outlined in table 
1. Compared to non-LACC patients, patients with LACC-noMV as 
well as those with LACC-MV experienced more preoperative tumor 
complications (34% vs. 51% and 52% respectively). The percentage of 
procedures in emergency/urgent setting was 14% for non-LACC and 
33% and 29% for LACC-noMV and LACC-MV patients, respectively. LACC 
was associated with a higher proportion of nodal positivity compared to 
non-LACC. Within the LACC group, nodal positivity was higher for LACC-
noMV compared to LACC-MV (60% vs. 47%). 
The surgical procedure commenced laparoscopically in 53% of patients 
with non-LACC, in 36% of those with LACC-noMV and in 21% of those 
with LACC-MV. Conversion rates were 13%, 19% and 52%, respectively. 
The proportion of primary anastomoses was considerably lower in 
LACC-MV patients compared to LACC-noMV and non-LACC patients 
(table 1). 
Guideline adherence
Preoperatively, a CT-abdomen at the least was performed in 92% of 
patients with LACC-noMV and in 95% of the patients with LACC-MV 
(table 2). These percentages were slightly higher (94% and 96%, 
respectively) if emergency/urgent procedures are excluded. Patients 
undergoing elective surgery were discussed during a MDT meeting 
in 80% and 82% of LACC-noMV and LACC-MV patients, respectively. 
Considering cT4 stage in the elective setting only, 6.2% (n=22) of 
patients with LACC (either no-MV or MV) received neoadjuvant (chemo)
radiotherapy and 4.0% (n=14) neoadjuvant systemic therapy. 
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Outcome variables
As compared to non-LACC, the overall R0 resection proportion was 
lower in LACC patients (99% vs. 90% respectively) (table 3). A higher 
proportion of R1/R2 resections was found for LACC-MV as compared to 
LACC-noMV (p <0.001), also in the elective setting only (p<0.001).  R0 
resection proportions were significantly higher in the elective setting 
as compared to the emergency and urgent settings for both LACC-noMV 
(93 vs. 87%; p<0.001) and LACC-MV (90% vs. 81%; p<0.001). In the 
LACC-noMV group, the R0 resection proportion was significantly lower 
in converted procedures than in laparoscopically completed resections 
(89% vs. 96%; p<0.001) though similar R0 resection proportions 
were found in the LACC-MV group (90% after conversion vs. 93% after 
laparoscopy). The R0 resection proportions following any form of 
neoadjuvant treatment did not significantly differ from the  
overall groups. 
In table 4, data on the postoperative course are displayed. The length 
of stay was the longest for the LACC-MV subgroup. Additionally, 
complications occurred most often in the LACC-MV group. 30 day / 
in-hospital mortality rate was significantly higher for LACC compared 
to non-LACC (5.8% vs. 3.6%; p<0.001) without significant impact of 
multivisceral resection (p=0.606) in LACC patients (table 4). 
Patients with LACC-MV were treated in all 92 hospitals. Based on the 
number of LACC-MV patients treated, the hospitals were subdivided into 
low (≤5 procedures annually) and high (>5 procedures annually) volume 
hospitals. There were 82 low volume hospitals (median volume 2.3; 
range 0.2-5.0) and 10 high volume hospitals (median volume 6.9; range 
5.2-8.2). The R0 resection proportion was 86% in low volume hospitals, 
as compared to 91% in high volume hospitals (p=0.024). 
When looking at the development of the quality of surgical care 
throughout the years, a significantly positive trend in completeness of 
resection, postoperative complicated course and 30 days / in-hospital 
mortality could be observed in the non-LACC and LACC-noMV groups in 
figure 2. These improvements were less clear (and non-significant) in 




This population study reports on clinicopathological characteristics, 
treatment strategy and short-term outcomes after resection of M0 LACC 
in 4,980 patients, who comprise 13% of the registered patients who 
underwent resection for colon cancer during a 6-year study period in 
the Netherlands. Only a small proportion of LACC patients was treated 
with neoadjuvant chemo- and/or radiotherapy. The overall R0 resection 
proportion was 90% in LACC patients, with the lowest proportion 
being 81% for patients who underwent a multivisceral resection in a 
non-elective setting. LACC patients had a slightly worse postoperative 
outcome compared to non-LACC patients. Short-term outcomes 
improved over time for LACC-noMV with the R0 resection proportion 
exceeding 95%. For LACC-MV, improvement over time was less clear and 
the R0 resection proportion in 2014 was 88%. 
An R1 resection of a primary colon cancer has a strong and stage 
independent negative prognostic impact on the survival and recurrence 
rate.8 In a recent single institutional cohort study, recurrence rates 
were 56% and 19% for R1 and R0 resection, respectively, with 
corresponding 5-year survival rates of 25% and 60%.9 Similar to our 
findings, the risk of incomplete resection was related to the T stage. 
R0 resection proportions were remarkably low: 65% for T4a and 
50% for T4b. Another population based study reported a 75% R0 
resection proportion in 861 patients with T4a stage colon cancer.10 
These data from literature and our findings suggest that there is room 
for improvement in LACC surgery. This will have a positive impact 
on prognosis given its independent association with recurrence and 
survival. Furthermore, the postoperative mortality for LACC of 5.8% 
also suggests room for improvement. This mortality rate is comparable 
to published series on LACC (3.3 – 8.9%)11–13.  However, this is a 
population-based study of unselected patients including emergency 
surgery and non-expert centers. The volume-outcome relationship in the 
present analysis suggests the potential benefit of further specialization 
and centralization of care in high volume centers. The small differences 
in absolute numbers of procedures between ‘low’ and ‘high’ volume 
hospitals (2.3 vs. 6.9 respectively), as well as the relatively low median 
volume in the ‘high’ volume group (6.9), show that LACC surgery has not 
yet been centralized in the Netherlands. Further improvement might 
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be expected when annual volumes exceed 15 to 2014. The low hospital 
volumes for LACC-MV might also explain the absence of improvement 
over time for LACC-MV.  Furthermore, lower R0 resection proportions in 
the emergency and urgent settings suggest a potential role for bridging 
strategies, such as a decompressing stoma. This would enable optimal 
staging, potential neo-adjuvant treatment and elective surgery by an 
optimal surgical team.
A multivisceral resection is essential to achieve a R0 resection in pT4b 
stage colon cancer and has been associated with improved outcome 
at population level.15 However, preoperative as well as intraoperative 
assessment of organ involvement is often inaccurate, because of 
the difficulty in distinguishing between true tumor invasion and 
inflammatory adhesions.16,17 Reported ‘true’ pT4 rates in multivisceral 
resections were 55, 36 and 34% in three studies. 12,18,19 Therefore, 
multivisceral resection often turns out to be overtreatment. This 
is a clinically relevant problem because of the increased morbidity 
rates as shown by our results and others.13,17 Despite its drawbacks, 
a multivisceral resection seems to be preferred over a less radical 
approach in clinically adherent tumors with uncertainty regarding the 
extent of malignant invasion, bearing in mind the negative prognostic 
impact of an irradical resection.20–22
In addition to extensive surgery, neoadjuvant therapies could optimize 
R0 resection proportions in LACC.23,24 In contrast to other types of 
gastrointestinal cancer, administration of neoadjuvant therapy in 
colon cancer remains uncommon.10,13,25,26 Incidental use of a variety 
of neoadjuvant therapy schedules has been described. In the phase-II 
Foxtrot trial,5 150 patients with LACC were randomized (2:1) between 
an experimental arm with preoperative chemotherapy (FOLFOX) and a 
second randomization in RAS wild type for an anti-EGFR antibody, and 
a control arm with routine adjuvant chemotherapy only. Preoperative 
systemic therapy was shown to reduce tumor size and resulted in a 
significant improvement of R0 resection proportion (96% vs. 80%). The 
need for emergency or urgent surgery, complication rate and toxicity 
were comparable across both groups. These findings were confirmed 
in another phase II study including 22 patients and the PRODIGE 
22-ECKINOXE trial with a similar design is currently recruiting. 27,28 In 
the present study, neoadjuvant therapy was not associated with a higher 
percentage of R0 resections. This may be the result of both small sample 
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size (n=77) and allocation bias, since the most advanced tumors were 
probably allocated to neoadjuvant therapy. 
Due to concerns regarding radiation toxicity, mainly concerning 
the small bowel, the use of (chemo)radiotherapy for LACC remains 
controversial.29 One study, in which 33 patients were retrospectively 
analyzed, suggested that neoadjuvant (chemo)radiotherapy combined 
with en bloc multivisceral resection results in high R0 resection 
proportions and excellent local control, with acceptable morbidity 
and mortality.16 In 64% of these patients, the T4 tumor was located in 
the sigmoid. The sigmoid was also the main tumor location (68%) in 
patients who received neoadjuvant (chemo) radiotherapy in the  
present study. 
Decisions on neoadjuvant therapy strategies should be based on 
preoperative imaging, but the accuracy is limited and over staging 
rates of up to 50% have been described.12,30 In this study a comparable 
discrepancy between cT4 and pT4 was found; in 833 of the pT4 patients, 
clinical T stage was registered with 61% being classified as cT1-3. 
Only 57% of the 578 cT4 tumors was classified as pT4 tumor. Despite 
its limited accuracy, preoperative imaging seems to be essential when 
considering neoadjuvant treatment and surgical planning. Therefore, 
further improvement can be expected from optimal guideline adherence 
with respect to preoperative imaging and MDT discussion. LACC is often 
considered to be a contra indication for laparoscopic surgery, due to 
oncological concerns. In this series, laparoscopic surgery was performed 
in 31% of LACC overall and 21% of LACC-MV with conversion rates of up 
to 52%. Conversion did not lower the R0 resection proportion in LACC-
MV patients, which suggests that it can be considered safe to initiate 
surgery laparoscopically. In contrast, conversion did result in lower 
R0 resection proportions in the LACC-noMV group. The latter finding 
is remarkable and was not confirmed in the literature. Several non-
randomized comparative studies have been published on laparoscopy 
in LACC.10,13,25,26,31,32 The laparoscopic group often had favorable baseline 
characteristics with regard to factors such as previous abdominal 
surgery and emergency setting. Additionally, resections were less often 
multivisceral. Conversion rates ranged between 7% and 24% and R0 
resection proportions were mostly similar to the open surgery groups. 
These data are most likely skewed by allocation bias. Increasing the rate 
of laparoscopic surgery for LACC might contribute to a lower morbidity 
rate, but this may never jeopardize oncological safety. 
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This is a large population based cohort study, which provides the best 
available evidence of the nationwide current clinical practice regarding 
LACC. However, several limitations of this design should be kept in mind. 
The availability of data is dependent on the self-reported data from the 
DSCA database, which is subject to registration bias and incomplete 
data registration. Nonetheless, data were validated on a yearly basis 
using the Dutch National Cancer Registry, in order to show accuracy and 
completeness of data6. Also, the variable set is chosen for the purpose 
of clinical auditing and several variables relevant to the aim of this 
study such as subdivision in T4a/b subgroups and organ involvement 
based on pathology reports are lacking. Additionally, the clinical T stage 
was unknown in a substantial number of patients, resulting in a small 
sample size of clinical T4 tumors, which is the relevant group to assess 
for neoadjuvant strategies. Furthermore, differences in patient and 
tumor characteristics between subgroups should be recognized when 
comparing outcome variables between the relevant subgroups.  
In conclusion, amongst patients who undergo surgery for LACC there 
is a lower R0 resection proportion and they are at higher risk of 
postoperative complications and mortality as compared to patients who 
receive surgery for less invasive colon cancer. Neoadjuvant therapy for 
colon cancer is still rarely applied in the Netherlands and prospective 
randomized studies have to be awaited in order to confirm the 
observation of more radical resections in phase 2 studies. Considering 
the relatively low R0 resection proportion, there is an opportunity for 
improvement. This may be achieved by optimizing preoperative imaging, 
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Figure 1. Subdivision of patients into non-LACC, LACC-noMV and LACC-MV. 
LACC: locally advanced colon cancer, MV: multivisceral resection required. 
Figure 2. The development of the quality of surgical care for LACC 
throughout the years.  LACC: locally advanced colon cancer, MV: multivisceral 
resection required. R1: incomplete resection with microscopic surgical 
resection margin involvement, R2: incomplete tumor resection with gross 
residual tumor that was not resected. Postoperative complicated course: 
postoperative complication leading to a re-intervention, hospital stay longer 
than 14 days, or death.

Chapter 9
GENERAL DISCUSSION AND FUTURE PERSPECTIVES
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PART I: RISK-ADJUSTMENT IN CLINICAL AUDITING
Patient populations treated for a specific condition usually differ across 
hospitals.1 Casemix is a confounder for between-hospital comparisons 
based on outcomes and therefore, casemix adjustment needs to be 
applied when comparing outcomes across hospitals with the aim to 
judge quality of hospital care. The casemix correction models are 
logistic regression models that include the most important predictors 
of the outcome parameter that are available in the audit.2 Despite 
incorporating casemix adjustment, many risk adjustment models could 
be considered suboptimal.3 In casemix adjustment we come across 
several problems. When comparing hospitals there is always random 
variation; fluctuations in outcomes of hospitals based on chance.4 
Random variation becomes smaller when the study population and 
frequency of events (the studied outcome) increases. This is specifically 
important regarding the fact that some serious but infrequent adverse 
events – like mortality rates - gain much attention in colorectal cancer 
care. The frequency of postoperative mortality, especially after rectal 
cancer resections is low and hospital variation could be due to random 
variation instead of a difference in performance. 
Another problem associated with casemix adjustment is the low 
frequency of specific patient populations in the majority of hospitals, 
while these are overrepresented in a few centres. The population of 
referral centres consist of a carefully selected group of patients based 
on the rarity of the disease or the high complexity of the treatment. 
These referral centres have a significantly different patient population, 
but are compared with general hospitals in one casemix correction 
model (this thesis). In chapter 2 we demonstrated that variable effects 
of predictors that are included in the currently used casemix model 
differed between referral and non-referral centres when we created 
separate casemix models for these two populations. As we hypothesized 
casemix correction models based on the total population showed the 
most resemblance with the non-referral population. The currently used 
casemix model (general model) that is fitted in the total population 
performs equally well in the non-referral population as a casemix model 
specifically fitted in non-referral hospitals only. In contrast, the general 
model performs worse in the referral population when compared to a 
model specifically fitted in referral hospitals only. It remains unclear 
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if the differences in casemix correction caused undercorrection for 
referral centres (this thesis). However no referral hospital was an 
outlier on the outcomes that were studied within the time frame  
of this study. 
It seems plausible that a bigger gain lies in the registration of typical 
characteristics of the referral population as the DSCA casemix models 
only include the most frequently occurring factors of influence.2 For 
hospitals with a specific patient population, like referral centres, 
it seems plausible that the registration of certain factors that are 
typical for this group of complex patients; i.e. detailed information 
about previous surgery, index surgery, multimodality treatments, and 
medication use therefore could be of influence on the correction of 
postoperative outcomes. Furthermore factors dictating the technical 
difficulty of the procedure are difficult to register with clear definitions 
– such as the detailed information about previous surgery – leading 
to suboptimal correction of postoperative outcomes. The possible 
solutions to these problems have their own disadvantages. Adding  
more variables to the dataset would make the registration burden  
bigger and the DSCA wants to keeps the dataset compact for users. 
Creating two separate casemix correction models would raise the 
question which hospital should be added to which population group. 
Beside from all university hospitals and two other hospitals that are 
generally seen as referral centres it is complex to decide whether 
hospitals treat a sufficiently different population in order to be 
compared to referral centres. 
Interpretation of hospital comparisons
A certain amount of unmeasured confounding in casemix correction of 
outcomes will remain, meaning that even casemix adjusted outcome 
rates should always be interpreted with caution. This is especially 
important as there is a growing demand for public transparency 
of hospital outcomes. Hospitals and surgeons are naturally held 
responsible for their outcomes and transparency to a public that is 
not informed on how to interpret this data could lead to unwanted 
reactions, such as the avoidance of high-risk surgery.5 Healthcare 
providers are less willing to register openly if this leads to adverse 
reactions and this disturbs the audit cycle. Therefore it is important that 
transparency is carefully introduced with the necessary information to 
interpret the data. Herein lies an important task for the national audits. 
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PART II: QUALITY ASSURANCE AND IMPROVEMENT IN DUTCH 
COLORECTAL CANCER CARE 
Quality assurance is an important aspect of the healthcare industry. All 
components of the patient’s healthcare process are of importance and 
influence the overall quality of treatment. Ernest J. Codman already 
noted at the beginning of the 20th century that careful registration of 
healthcare processes and patient outcomes would provide important 
feedback information. He wanted an end-results system to track the 
outcomes of his patient’s treatments as an opportunity to identify 
clinical misadventures that would serve as the foundation for improving 
the care of future patients.6 Doctor Codman was ahead of his time and 
was expelled from the staff of the Massachusetts General Hospital.7 
Fortunately his ideas on quality of care are regarded as highly relevant 
nowadays.8, 9 
Hospital volume
New thoughts on quality assurance at the beginning of this century 
were largely focussed on the relationship between hospital or surgeon’s 
volume and quality.10-16 This relationship was also analysed in the 
Netherlands with multiple papers describing the positive relationship 
between hospital volume and patient outcomes.17-19 
The Netherlands is a small country with 90 hospitals. As a result low-
volume high-risk procedures could be centralized in a smaller number 
of hospitals, with acceptable travelling distances for patients.17 Besides 
the fact that a larger volume per surgeon will lead to more experience, 
it is generally believed that volume is a ‘proxy’ for other important 
structural and process factors in the chain of multidisciplinary 
treatment.20 
This further enhanced centralisation of technically challenging 
procedures such as rectal-, pancreas-, oesophageal- and bladder 
cancer resections. The Association of Surgeons of the Netherlands 
(ASN) set an obligatory minimal volume standard of 20 resections 
per hospital per year.21 Hospitals with lower annual volumes of rectal 
cancer resections are no longer allowed to carry out this procedure. 
With data from the DSCA this decision could further be substantiated 
(this thesis). Chapter 3 shows the significant influence of hospital 
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volume on CRM involvement in the Netherlands. In the light of these 
results an obligatory volume for rectal cancer care seems justifiable. 
It is however important to conclude that hospital volume is merely 
a proxy for healthcare processes and that hospital volume does not 
guarantee quality.22 Individual small volume hospitals can provide the 
same standard of care compared to high volume hospitals as shown in 
this thesis. Over the last years focus has shifted towards value of care 
instead of volume of care.23, 24 
Clinical auditing
Amongst other initiatives the DSCA was founded in 2009 and provides 
risk-adjusted benchmarked feedback evaluating quality of surgical 
colorectal cancer care on hospital level and compares hospitals with 
their peers. It gives surgeons and their teams information about their 
performance and stimulates the development or improvement of 
hospital processes.2 Amongst other great improvements in the field 
of colorectal cancer surgery the introduction of clinical auditing has 
been successful.2, 25 Important aspects of surgical colorectal cancer care 
improved significantly since the start of the audit. As clinical auditing 
provides healthcare professionals with essential information on their 
performance in comparison to their peers, multiple improvements 
can be made. There are several requirements for surgical audits to 
provide valuable information.26 The definitions used in the surgical 
audit should be unambiguous and feedback information should be 
reliable, accompanied by a risk-adjusted benchmark. Furthermore 
the information has to be up to date and easily accessible to involved 
healthcare providers. Most importantly the feedback information should 
be relevant, meaningful and actable which necessitates the formation 
of the surgical audits content by those personally engaged in the 
surgical activity concerned.6 In addition, the effect of clinical auditing 
in hospitals is probably influenced by the attitude of the healthcare 
providers towards the national audit. Are surgical teams learning 
from their data and are they keen to start improvement projects or 
are they merely collecting this information as an obligatory burden? 
In the Netherlands, 86% of colorectal surgeons discuss their results 
periodically with their colleagues and 76% started improvement 
projects in response to the DSCA. The majority of colorectal surgeons 
are content with the DSCA.27
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The basis of clinical auditing is an intrinsic motivation of medical 
professionals to improve the care they provide. Nevertheless it is 
known that intrinsic motivation is subject to daily change, it lies in the 
human nature. The so-called Hawthorne effect is a type of reactivity in 
which individuals modify an aspect of their behaviour in response to 
their awareness of being observed.28 This is a bothersome effect in the 
interpretation of results of medical research but a welcome effect in 
clinical auditing. Due to this effect the DSCA stimulates the quality of 
care that is measured. If problems in healthcare processes get identified, 
the national audit can give extra attention to these aspects (this thesis). 
Awareness usually leads to quality improvement projects and in depth 
investigation of underlying problems.27 When this action has led to the 
aimed results – i.e better national mean outcome and decreased hospital 
variability - the raised awareness can be loosened and registration of 
the item could be stopped to keep the registration burden manageable 
(figure 1). Sometimes this loosened awareness causes old hiatus to come 
back. When data sources are linked in the future it might get easier to 
periodically bring these aspects back to the attention, as this would not 
imply greater registration burden.
CRM registration and involvement
At the start of the DSCA the percentage of patients with a resection for 
rectal cancer that had a reported CRM was only 50 percent (chapter 4). 
The CRM is a significant prognostic factor for local recurrence, distant 
metastasis and survival after rectal cancer surgery.29, 30 Before – at the 
time of the Dutch TME trial (1996-1999) - the availability of the CRM 
due to a standard pathology report, which included the CRM, had been 
an important aspect of the study.31 During this period reporting of CRM 
was therefore high (97%) in participating centres.32 We can conclude 
that focus on registering the CRM greatly diminished after the Dutch 
TME trial had finished. Another conclusion we can extract from this 
information is that trial data not always represent real life data. Only 
3 years after the start of the DSCA CRM reporting improved to 94.2 
percent nationally (chapter 4). We think that this improvement in CRM 
reporting is almost exclusively attributable to the increased awareness 
of the healthcare providers raised by national audit (this thesis). Due 
to renewed focus in each hospital this valuable information on the 
quality of surgery and on the long-term prognosis of the patient became 
available again to the healthcare providers.  
173
CHAPTER 9
During the first five years of the DSCA registration incidence of CRM 
involvement decreased from 14 to 6 percent; an absolute reduction of 
more than fifty percent (chapter 4). Clinical auditing lays tremendous 
focus on the outcome of the CRM, which was, to our opinion, a driving 
force for the significant improvement of this outcome parameter leading 
to better long-term outcomes for rectal cancer patients. Furthermore 
the DSCA stimulated guideline adherence leading to a higher percentage 
of patients that were preoperatively discussed in a multidisciplinary 
team (MDT) meeting.2 The stimulated guideline adherence led to 
a higher percentage of patients in whom local staging by MRI was 
performed. Both improvements could have attributed to the quality 
of rectal cancer surgery (this thesis). The present analysis shows that 
quality indicators play an important role in identifying quality concerns 
and variation, and enable targeted quality improvement projects. Few 
other interventions in the care of rectal cancer patients have led to such 
magnitude of improvements in a relatively short period of time and it 
shows the value of national auditing as a tool for quality improvement. 
Furthermore, centralisation of the technically challenging rectal cancer 
surgery has had significant influence on CRM involvement (chapter 3). 
The minimal annual volume of 20 rectal cancer resections has had a 
positive influence on CRM involvement. 
International comparisons
The information from the DSCA makes it easier to compare current 
national practice in the Netherlands with international peers. As 
described in chapter 5 of this thesis, van Leersum et al. found that the 
use of radiotherapy for patients with stage I / low-risk stage II rectal 
cancer (cT1-3N0) in the Netherlands was high compared to other 
European countries.33 The national audit therefore increased national 
insight on this subject and raised awareness in Dutch hospitals of being 
the European exception regarding RT-use. This laid the foundation for 
guideline revision and the fast implementation by healthcare providers 
afterwards (chapter 5). Our study shows the impact of the revised 
national colorectal cancer guideline immediately after it became available 
to the community. The use of radiotherapy in patients with cT1N0 
disease was abandoned and radiotherapy treatment in patients with 
cT2-3N0 disease significantly decreased within one year (this thesis). 
In addition to guideline revision as the ultimate tool to rapidly change 
clinical practice, it appears to be very important to create a well-informed 
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medical field. Secondly the audit is a useful tool to verify whether the 
changed indication for radiotherapy altered postoperative outcomes. This 
thesis shows that CRM involvement did not increase after RT-use radically 
changed (figure 2). Clinical auditing in this case proves to be a useful tool 
for quality control after guideline revision. 
PART III: DATA FROM CLINICAL AUDITS AS A SUPPLEMENT TO 
RCT’S
Hospital outcome variation can be the result of differences in the 
structural and procedural differences between hospitals.34 The higher 
the degree of variation between hospitals on a particular subject the 
more we can usually learn from this information. The national audit is 
a rich source that can be used for such research. The audit provides us 
with “real-time” information as the data is frequently updated and it 
provides us with “real-world” data as all patients are included, meaning 
all patients who underwent resection of colorectal cancer in case of the 
DSCA. This part of the thesis provides examples of how clinical audit 
data is used to answer several clinically relevant questions in the field 
of surgical treatment of colorectal cancer.
Laparoscopic colorectal surgery
Laparoscopic surgery has been a major change in abdominal surgery.35 
The technique was introduced by gynaecologists and in the 90’s adapted 
by other specialists.36, 37 In colorectal cancer surgery, laparoscopic 
surgery resulted in faster postoperative recovery compared to 
conventional open surgery, without compromising oncological 
outcomes.38, 39 Long-term benefits of laparoscopic surgery for colorectal 
cancer are better cosmetics, less incisional hernias due to preserved 
abdominal wall integrity, and less adhesion related small bowel 
obstruction.40-42 Due to these results laparoscopic surgery makes up for 
the majority of colorectal cancer surgery in present times.43 
Randomized controlled trials can provide solid prove on non-inferiority 
of new techniques. But this type of research comes with some 
drawbacks; i.e. they take a long time to conduct, handle strict inclusion 
criteria and usually do not include large numbers of patients.44 These 
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issues can cause clinically relevant questions to remain unanswered.35 
In chapter 6 we describe an example; is laparoscopic surgery in 
colorectal cancer care influencing postoperative mortality? This remains 
unanswered because mortality was a rare event in most RCT’s including 
a relatively low-risk population. As the technique is already widely 
introduced and next to the earlier mentioned unwanted characteristics 
of the RCT regarding this subject, the effectuation of an RCT on the 
matter would no longer be regarded ethically sound. This chapter shows 
that population studies are able to include higher numbers of patients 
with different operative risk levels from daily clinical practice showing 
interesting results. It demonstrates the significantly reduced risk of 
postoperative mortality after laparoscopic surgery compared to open 
surgery in patients with non-locally advanced, non metastatic colon 
cancer in an elective setting. Moreover it endorses the hypothesis of  
the positive influence of laparoscopic surgery on postoperative 
outcomes in elderly patients with or without comorbidity.45-47 To 
deal with the inherent methodological problems of non-randomized 
comparisons, a risk-stratified comparison between relatively 
homogenous subgroups using raw data was used, thereby minimizing 
selection and allocation bias.
Ideally all developments in medicine should be extensively tested 
before they are introduced to patient care. However development is an 
important element of quality assurance and healthcare professionals in 
all area’s need to keep up with latest developments. There is a thin line 
between fast introduction of new techniques and providing evidence-
based medicine. In reality techniques are already implemented while 
large randomized or prospective studies are still running.48 A national 
audit can be used to monitor the implementation of new techniques 
providing regular feedback of patient outcomes to the surgical teams. 
If a relatively high number of adverse events would be observed, the 
professional society and their members can take actions.
Kolfschoten et al. analysed the introduction of laparoscopy for colorectal 
cancer in the Netherlands and concluded that the introduction had been 
completed safely.49 In the Netherlands the percentage of laparoscopic 
colorectal cancer resections is high, especially compared to the 
surrounding countries. We may therefore expect that the learning curve 
in the Netherlands has been passed through with better postoperative 
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outcomes at present.50 Furthermore, laparoscopy encouraged the 
subspecialisation of colorectal surgeons, further enhancing surgical 
quality. Moreover laparoscopic surgery became available for the 
technically more challenging patients, and now those are also profiting 
from its short- and long-term advantages (this thesis). Frequently 
quoted outcomes after laparoscopic surgery however are from older 
RCT’s such as the COLOR II trial.51 Chapter 7 complements older studies 
by showing the current outcomes of a comparable population, matched 
to the Dutch population of the COLOR II trial. This study demonstrates 
that patient outcomes after laparoscopic surgery for rectal cancer 
largely improved and that older RCT’s do not provide representative 
outcomes anymore. It shows once again the value of national audits 
because they are able to provide us with real-time data and an accurate 
representation of national performance. 
High-risk patients 
Healthcare industry is naturally ever changing. Due to the aging 
population, patients with colorectal carcinoma are older and have 
a higher perioperative risk.46 Furthermore there is growing interest 
for patient-tailored treatment.52 Different patients and tumor 
characteristics benefit from tailored treatment. Not surprisingly, this 
has an effect on the treatment of colorectal cancer patients. With these 
changes there is a need for real-time and real-life data, providing us 
with end results after specific treatment schedules, changed processes 
and providing us with data on specific patient groups. A significant 
proportion of colorectal cancer patients are underreported. They are 
excluded from RCT’s due to advanced disease, multiple-comorbidity 
or their age. For instance, if you apply the exclusion criteria of the 
COLOR II trial (chapter 7) to the DSCA population in 2014, only 70% of 
patients with a laparoscopic resection for rectal cancer would have been 
included in the COLOR II trial. 
Chapter 8 describes the clinical-pathological characteristics, treatment 
strategies and short-term outcomes after resection of 6,918 patients 
with locally advanced colon carcinoma (LACC), comprising 17.5% of the 
registered patients who underwent resection for colon cancer during 
a 6-year study period in the Netherlands. Hospital variation regarding 
this oncological high-risk frail patient population is informative. Best 
practices might be able to educate us on improving outcomes for this 
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fragile patient population that deserves more attention.53 As high-risk 
patients are underreported in large RCT’s shared decision-making 
is difficult in this population. LACC patients for instance had worse 
postoperative outcomes compared to non-LACC patients regarding 
length of hospital stay, complication rate, re-intervention rate and 
mortality rate (chapter 8). There has been much more interest in rectal 
cancer surgery during the past decades, and it is only in recent years 
that focus on LACC is increasing. Audit data can be used in this way to 
provide information for identifying areas for potential improvement 
and knowledge gaps that necessitate new research. From a patient 
perspective, these data can help in shared decision making and 
managing of expectations.
FUTURE PERSPECTIVES 
Due to the accomplished successes of clinical auditing the need for 
clinical feedback information of healthcare providers will grow. This 
thesis shows the usefulness of real-world and real-time data provided 
by clinical audits. It not only serves as risk-adjusted feedback to 
healthcare providers, it serves other important causes as well by 
providing clinical information of a merely non-selected group of 
patients. Growth in these areas of usage is needed and expected.44 
Clinical audits already provide information on specific groups of 
patients that are underreported in literature. Outcomes research 
in this patient population is providing important information for 
shared decision-making in the clinical setting. The inclusion of patient 
reported outcome measurements (PROMS) can potentially deepen 
this information by linking on patient level to structure – process and 
outcome data. This information should be at hand in daily clinical 
practice and patients could then be informed on the clinical outcomes 
and patient reported functional outcomes of patients like them who 
received different types of treatment. Although interpretation of such 
data might still be difficult due to, for example, relevant inter-individual 
variability in perceiving treatment effects.  
This thesis provides a clear example of how international treatment 
variation can lead to practice change in the Netherlands. Through 
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international comparison we became aware of the overuse of 
radiotherapy in rectal cancer treatment, which led to the revision of 
the national guideline on the treatment of rectal cancer (chapter 5). 
International benchmarking will bring forth extensive practice variation 
– regarding structural, process and outcome measurements - making it 
a rich source of valuable clinical feedback information and outcomes 
research. Orientation towards international clinical auditing is growing 
with the set up of multiple European initiatives like EURopEan CanCer 
Audit (EURECCA) or European Reference Networks (ERNs).54, 55 
International audits should be erected with unambiguous definitions, 
which is challenging due to existence of multiple national initiatives. 
The ICHOM colorectal cancer set is a good example of an internationally 
available compact set of outcome measurements composed by 
professionals and patients, which can be implemented in every hospital 
around the globe.56 This does not only apply to audit data; all data in 
healthcare should be reusable for other parties in order to get the most 
out of it. The FAIR data principles act facilitated by a broad community 
of international stakeholders is a good example of the lobby for the 
reusability of data holdings for sharing knowledge around the globe.57 
FAIR data pleas for good data stewardship with findable, accessible, 
interoperable and reusable data. 
The fast spread and implementation of (future) innovations necessitates 
reliable data registration systems. Clinical audits, connected to other 
data systems, should be part of such registration systems, connecting 
registered new techniques to clinical outcomes and PROMs. As not all 
changes can be extensively tested – i.e in RCT’s – these registration 
systems could play a part in the safe implementation of new techniques 
and enabling timely intervention in the case of adverse events.58 
Connection to other data systems will give insight in the influence of 
clinical changes on healthcare costs and provide information on costs 
effectiveness of clinical innovations.59 In this way clinical auditing could 
play a major role in providing value based healthcare.
There is an on-going transition from intervention-centered clinical 
audits to multidisciplinary, patient-centered clinical audits. The DSCA 
started as a monodisciplinary clinical audit in 2009, concentrated 
around the surgical resection for patients with colorectal cancer and is 
slowly changing to a multidisciplinary audit. Now gastro-enterologists, 
radiologists, radiotherapists and medical oncologists joined the audit 
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changed its name recently to the multidisciplinary Dutch ColoRectal 
Audit (DCRA). A full transition to a patient-centered audit is yet to 
be completed, as only patients with a resection for colorectal cancer 
are currently registered. In order to create the ultimate patient-
centered clinical audit patients receiving only adjuvant treatment or no 
treatment at all should be included. Only then the audit will provide us 
with complete information on clinical care and outcomes without the 
current blind spot of patients that fall behind the inclusion criteria of 
the clinical audits. This will create the true basis for shared decision-
making as patients can get all the information that is available on 
patients like them who underwent different types of treatment or no 
treatment. Moreover such a system would create a rich resource for 
further outcomes research bringing valuable new insights to the whole 
medical community. 
An extensive patient-centered registration system will not be able 
without far-going connection between multiple data-systems. Again 
this underlines the importance of data that is recorded once at its 
source that is suitable for data connection and for re-use in different 
settings. In this way information is gathered with minimal registration 
burden for healthcare providers. The DCRA started recently with the 
inclusion of synoptic reporting of surgical resections in the clinical 
audit. Furthermore the structural input of pathology reports in the audit 
is already effectuated by a connection to PALGA (the national archive of 
pathology data). 
END CONCLUSION
This thesis shows the value of outcomes research with clinical audit 
data. Real-world and real-time data of clinical audits complement RCT’s 
due to large numbers of patients and the inclusion of high-risk patients. 
Furthermore they provide a basis for international comparison and 
valuable information on patients that are excluded from RCT’s and 
underreported in literature. The evolution of clinical audits to patient-
centered registrations and the connection with multiple other data 
registrations will lay the basis for a registration system that can be 
used for shared-decision making, providing value-based healthcare and 
further extensive outcomes research.
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Figure 1a,b, and c. Patients with pT2 colon carcinoma with a minimum of 10 
examined lymphnodes by a pathologist per hospital in 2009, 2011, and 2013. 
Figure 2. Use of preoperative radiotherapy for rectal cancer in the 
Netherlands for different clinical stages and the percentage of patients with 









Colorectal cancer is a major contributor to the health burden 
worldwide. As the heterogeneity of patients and tumor characteristics 
increases, there is a growing need for timely and reliable information 
that measures the quality of treatment in these populations; so-called 
real-world and real-time information. In 2009 the Dutch Colorectal 
Audit (DCRA), formerly known as the DSCA, started, which includes all 
patients undergoing a resection for colorectal cancer. Clinical audits  
are rich databases that provide a unique source of up to date 
information without the strict inclusion criteria that apply to 
randomised controlled trials (RCT’s) and therefore complement the 
latter. This thesis describes the value of clinical audit data in colorectal 
cancer care and furthermore discusses the inherent statistical problems 
encountered in population studies. 
Part I: Risk-adjustment in clinical auditing
When hospital outcomes are compared the validity of these comparisons 
is essential. Hospital outcomes are corrected for casemix. A casemix 
model is a tool designed to measure patient complexity by using a 
system of identifiable patient/tumor factors applied to a weighted 
scoring system in relation to the postoperative outcome. In this way 
the outcome of hospitals can be corrected for the complexity of their 
patient population for fairer comparisons. In oncology there is a trend 
towards centralisation of specific patient subgroups based on the rarity 
and complexity of their disease in so called referral hospitals. At this 
moment outcomes of non-referral and referral hospitals are corrected 
for casemix with the same casemix correction model. Chapter 2 shows 
that referral hospitals treat a significantly different population and that 
the effect of casemix variables on postoperative complicated course 
differs in weight between non-referral and referral hospitals. The study 
demonstrates that the currently used casemix model is mostly dictated 
by non-referral hospitals and thereby shows most resemblance to the 
non-referral hospitals. A casemix model specifically fitted to the referral 
population performs better then the currently used casemix model 
in the referral population. Whether it would be advisable to use two 
separate casemix models for non-referral and referral hospitals is not 
clear and further research is required. 
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Part II: Quality improvement in the Dutch colorectal cancer care
Changes in colorectal cancer surgery over the last years include 
amongst other things the implementation of minimum volume standards 
for colorectal cancer surgery and the start of the DCRA providing 
regular casemix corrected benchmarked feedback to the medical team. 
In order to detect areas that request further improvement audit data 
can be used for international comparison.
Chapter 3 analyses the effect of hospital volume on the outcome of 
circumferential resection margin (CRM) involvement. The CRM is a 
significant prognostic factor for local recurrence, distant metastasis and 
survival after rectal cancersurgery.
From 2014 the Dutch Society of Surgery stated a compulsory minimal 
volume standard of 20 rectal cancer resections per hospital, following 
the multiple publications on the positive relationship between volume 
and postoperative outcomes. This chapter shows an independent 
and significant relationship between volume (<20) and CRM and 
demonstrates that patients treated in low-volume hospitals had a 1.5-
fold higher risk of CRM involvement than patients operated in high-
volume hospitals. Therefore it supports the minimal annual volume 
standard for rectal cancer surgery, leading to better oncological 
outcomes, attributing to a better prognosis for these patients.
Chapter 4 shows that there has been a dramatic improvement in 
CRM reporting and a major decrease of CRM involvement after rectal 
cancer surgery since the start of the DCRA. Population based studies 
and other national audits on rectal cancer confirmed that the CRM, as 
an important measure for the quality of surgical resection, was often 
lacking in the pathology report. This study describes that the mean 
percentage of patients with a reported CRM increased from 52.7 to 
94.2 percent (2009-2013) and interhospital variation decreased. The 
percentage of patients with CRM involvement decreased from 14.2 
to 5.6 percent. Improvement in CRM reporting is almost exclusively 
attributable to the national audit, and the multivariable analysis 
included in this study also suggests that the DSCA was a driving force 
behind the significant increase in tumor free resection margins.
International comparison of audit data can identify differences in 
treatment modalities between countries. The rate of preoperative 
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radiotherapy (RT) for rectal cancer in the Netherlands has been the 
highest among European countries. Data from the national audit 
showed significant overtreatment of early stage rectal cancers, which 
encouraged the revision of the national guideline on rectal cancer 
treatment. This revision specifically focussed on the indication for RT 
and MRI criteria to evaluate mesorectal lymph nodes in order to reduce 
overtreatment for patients with false positive cN1-2 disease. Chapter 5 
evaluates the implementation of the new guideline in the Netherlands 
and determines the diagnostic accuracy of preoperative MRI for nodal 
staging. The revised national guideline on colorectal cancer was rapidly 
implemented in the Netherlands with a substantial decrease in RT use 
for low risk resectable rectal cancer. The specificity of MRI for N staging 
increased, resulting in a decrease of false-positive results in 2014, 
leading to fewer patients with low-risk rectal cancer undergoing RT. It 
is believed that the national clinical audit has played an important role 
in the observed changes in clinical practice. The rapid implementation 
of the revised national guideline on colorectal cancer is a good example 
of the usage of audit data to instigate national practice change and to 
check its implementation afterwards.  
Part III: Data from clinical audits as a supplement to RCT’s
The third part of this thesis shows how clinical audit data is used 
for clinically relevant research. Due to the absence of preselected 
populations and large numbers of patients, clinical audits can analyse 
research questions that are unlikely to be answered in RCTs due to 
insufficient power. Furthermore it provides up to date information on 
the present-day quality of care and is able to evaluate care of patients 
that are underreported in literature.  
Chapter 6 analyses the rate of postoperative morbidity and mortality 
after open versus laparoscopic surgery for colorectal cancer in specific 
subgroups of patients, including patients with a high preoperative 
risk for adverse outcomes. Several meta-analyses of RCTs showed a 
trend towards lower postoperative mortality in favour of laparoscopic 
resection, but failed to reach statistical significance. The inclusion of 
relatively low risk patients and the lack of sufficient power are probably 
responsible for that. This study demonstrates a reduced mortality 
risk after elective LR compared to OR in patients with non-locally 
advanced, non-metastasized colorectal cancer. Especially elderly frail 
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patients (a priori high-risk patients) seem to benefit because of reduced 
cardiopulmonary complications. These findings support widespread 
implementation of LR for colorectal cancer, also in patients at high 
operative risk. 
LR for rectal cancer has been rapidly and safely implemented in 
the Netherlands, increasing to 83% of all rectal cancer patients in 
2015. The results of older randomised trials, i.e. COLOR II trial, are 
commonly quoted and as LS has a steep learning curve one might 
question whether the COLOR II data are still representative for current 
national performance. Chapter 7 analyses current oncological quality of 
laparoscopic surgery for rectal cancer in the Netherlands by performing 
a matched comparison of data from the DCRA and the COLOR II trial, 
using the CRM as main quality indicator. This study demonstrates 
improved oncological quality of laparoscopic surgery for rectal cancer 
in the Netherlands with a significantly lower percentage of CRM 
involvement, higher mean harvested lymph nodes and lower admission 
time, implicating that LS has been successfully implemented in the 
Netherlands. Secondly it provides an accurate representation of national 
performance regarding the laparoscopic resection of rectal carcinoma.
Chapter 8 shows the outcomes of patients with locally advanced colon 
cancer (LACC) in the Netherlands. The curative intent treatment for 
these patients is a complete resection of the tumor (R0 resection) 
followed by adjuvant systemic chemotherapy. An incomplete resection 
has a negative prognostic impact on long-term outcomes. Treatment 
of LACC is still an underexposed area in the field of colorectal cancer 
care and is not centralised in expert centres. Our study demonstrates a 
lower R0 resection proportion for patients with LACC and a higher risk 
of postoperative complications and mortality as compared to patients 
with less invasive colon cancer. Data from literature and our findings 
suggest room for improvement for patients with LACC. Improvement 
might be expected from optimized preoperative imaging, routine MDT 
discussions, bridging to surgery in emergency setting, and further 
specialisation and centralisation of care. Optimized use of neo-adjuvant 
treatment strategies based on already available and upcoming evidence 




Darmkanker draagt in belangrijke mate bij aan de wereldwijde 
ziektelast. Met de toenemende heterogeniteit van patiënt- en 
tumorkarakteristieken is er meer en meer behoefte aan tijdige en 
betrouwbare informatie die de kwaliteit van de behandeling in 
verschillende populaties meet en terugkoppelt; zogenaamde real-world 
en real-time informatie. In 2009 is de Dutch Colorectal Audit (DCRA), 
eerder bekend als de Dutch Surgical Colorectal Audit (DSCA), opgericht, 
die alle patiënten includeert die een resectie voor darmkanker 
ondergaan. Clinical audits zijn waardevolle databases die unieke actuele 
informatie bevatten omdat zij niet de strikte inclusiecriteria hanteren 
die van toepassing zijn op gerandomiseerd onderzoek (RCT’s). Hierdoor 
vormt audit data een belangrijke aanvulling op gerandomiseerd 
onderzoek. Dit proefschrift beschrijft de waarde van audit data in de 
darmkankerzorg en bespreekt daarnaast de inherente statistische 
problemen die populatie studies met zich mee brengen. 
Deel I: Correctie voor zorgzwaarte in clinical audits
Bij het vergelijken van ziekenhuisuitkomsten is de validiteit van deze 
vergelijking van essentieel belang. Ziekenhuisuitkomsten worden 
gecorrigeerd voor casemix, de zorgzwaarte van een patiëntenpopulatie. 
Een casemix model is een instrument dat de complexiteit van een 
patiëntenpopulatie berekend op basis van een gewogen scoringssysteem 
bestaande uit identificeerbare patiënt- en tumorkarakteristieken, 
waarvan het gewicht in relatie tot postoperatieve uitkomst gemeten 
wordt. Op deze manier kan de uitkomst van ziekenhuizen gecorrigeerd 
worden voor de complexiteit van hun patiëntenpopulatie, wat leidt tot 
eerlijkere vergelijkingen. In de oncologie is er centralisatie gaande van 
specifieke subgroepen patiënten in zogenaamde verwijsziekenhuizen op 
basis van de zeldzaamheid en complexiteit van de ziekte. Op dit moment 
worden resultaten van niet-verwijs en verwijsziekenhuizen gecorrigeerd 
voor casemix in hetzelfde casemix correctie model. Hoofdstuk 2 laat 
zien dat verwijsziekenhuizen een significant verschillende populatie 
behandelen en dat het effect van casemixvariabelen op de uitkomst 
“postoperatief gecompliceerd beloop” verschilt tussen niet-verwijs 
en verwijsziekenhuizen. Uit onze studie blijkt dat het casemixmodel 
dat momenteel gebruikt wordt, overwegend gedicteerd wordt door 
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de niet-verwijspopulatie en dat het gewicht van de variabelen in 
het model in relatie tot de uitkomst het meest lijken op de situatie 
in niet-verwijsziekenhuizen. Een casemixmodel dat specifiek op de 
verwijspopulatie is gefit, presteert beter dan het momenteel gebruikte 
standaard casemixmodel in de verwijs populatie. Of het raadzaam is om 
twee aparte casemixmodellen te gebruiken voor het terugkoppelen van 
de gecorrigeerde uitkomsten van niet-verwijs en verwijsziekenhuizen 
valt uit deze studie niet te concluderen; verder onderzoek is nodig.
Deel II: Kwaliteitsverbetering in de Nederlandse darmkankerzorg  
In de afgelopen jaren heeft de darmkankerchirurgie in Nederland 
veranderingen doorgemaakt; zo is er een volumenorm voor darmkanker 
resecties geïmplementeerd en is de DCRA van start gegaan die 
zorgprofessionals voorziet van tijdige en casemix gecorrigeerde 
gebenchmarkte terugkoppelingen. Verder wordt in deel II besproken hoe 
er, door middel van internationale vergelijking van audit data, gebieden 
in de zorg geïdentificeerd worden die aandacht behoeven.
Hoofdstuk 3 analyseert het effect van ziekenhuisvolume op 
een oncologische uitkomst; de circumferentiële resectie marge 
(CRM). De CRM is een significant voorspellende factor voor lokaal 
recidief, afstandsmetastasen en overleving na een resectie voor 
rectumcarcinoom. Vanaf 2014 stelde de Nederlandse Vereniging 
voor Heelkunde (NVvH) een verplicht minimaal jaarlijks volume 
van 20 rectumcarcinoom resecties per ziekenhuis in, op basis van 
wetenschappelijke studies die een positieve invloed van een hoger 
ziekenhuisvolume op postoperatieve resultaten aantoonden. Dit 
hoofdstuk toont een onafhankelijke en significante relatie tussen laag 
volume (<20) en een positieve CRM en beschrijft een 1,5 keer hoger 
risico op een positieve CRM voor patiënten die in een laag volume 
ziekenhuis zijn geopereerd vergeleken met zij die werden geopereerd 
in een hoog volume ziekenhuis. Dit onderzoek ondersteunt daarmee de 
volumenorm voor de chirurgische behandeling van rectumcarcinoom 
aangezien het leidt tot betere oncologische resultaten, wat samenhangt 
met een betere prognose voor de patiënt.
Hoofdstuk 4 toont de verbetering van het percentage gerapporteerde 
CRM en de begeleidende afname van het percentage positieve CRM 
na resectie van rectumcarcinoom na de start van de DCRA in 2009. 
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Populatiestudies en andere nationale audits toonden ook dat de 
CRM, een belangrijke maat voor de oncologische kwaliteit van 
de rectumresectie, vaak ontbreekt in het pathologie rapport. Dit 
onderzoek beschrijft dat het gemiddelde percentage patiënten met 
een gerapporteerde CRM in de DCRA steeg van 52,7 naar 94,2 procent 
(2009-2013) en dat de variatie tussen ziekenhuizen op het gebied 
van deze rapportage is afgenomen. Het percentage patiënten met een 
positieve CRM daalde van 14,2 tot 5,6 procent in diezelfde jaren. De 
verbetering van CRM rapportage is bijna uitsluitend toe te schrijven aan 
de nationale audit. Verder suggereert de multivariabele analyse in deze 
studie dat de audit een drijvende kracht is geweest achter  
de significante afname van het percentage patiënten met een  
positieve CRM. 
Internationale vergelijkingen van audit data kunnen verschillen in 
behandelingsstrategieën tussen landen inzichtelijk maken. Zo is 
gebleken dat het percentage preoperatieve (chemo)radiotherapie voor 
patiënten met rectumcarcinoom in Nederland hoog was in vergelijking 
met andere Europese landen. Gegevens uit de nationale audit toonden 
een substantiële overbehandeling van laag stadium (laag risico) 
rectumcarcinoom. Dit heeft ertoe geleid dat de nationale richtlijn 
colorectaal carcinoom is herzien. De gereviseerde versie heeft met 
name aandacht besteed aan de indicatie voor preoperatieve (chemo)
radiotherapie. Tevens zijn MRI criteria om mesorectale lymfeklieren te 
beoordelen aangepast om daarmee de overbehandeling te verminderen 
van patiënten gediagnosticeerd met vals positieve cN1-2 ziekte. 
Hoofdstuk 5 evalueert de implementatie van de gereviseerde richtlijn 
in Nederland en analyseert de diagnostische nauwkeurigheid van de 
preoperatieve MRI voor het bepalen van het N-stadium. De gereviseerde 
nationale richtlijn colorectaal carcinoom is snel geïmplementeerd 
in Nederland en heeft geleid tot een aanzienlijke daling van het 
aantal patiënten dat preoperatieve radiotherapie ondergaat voor 
laag stadium rectumcarcinoom. De specificiteit van MRI voor N 
stagering is toegenomen, wat heeft geresulteerd in een daling van 
patiënten met vals positieve cN1-2 ziekte in 2014, wat heeft geleid 
tot minder patiënten met laag risico rectumcarcinoom dat onnodig 
preoperatieve radiotherapie onderging. De nationale audit heeft naar 
alle waarschijnlijkheid een belangrijke rol gespeeld in de waargenomen 
veranderingen in de klinische praktijk. De snelle implementatie van 
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de gereviseerde richtlijn is een goed voorbeeld van het gebruik van de 
audit om nationale beleidswijzigingen in te zetten en de implementatie 
ervan voorts te controleren.
Deel III: Gegevens uit clinical audits als aanvulling op RCT’s
Het derde deel van dit proefschrift toont hoe audit data gebruikt kan 
worden als aanvulling op gerandomiseerd onderzoek. Zo kan je met 
audit data, door de afwezigheid van voorgeselecteerde patiënten 
populaties en grote aantallen patiënten, vraagstukken analyseren die 
niet beantwoord kunnen worden met RCT’s vanwege een tekort aan 
statistische power. De audit maakt verder de actuele kwaliteit van zorg 
inzichtelijk en biedt daarnaast informatie over patiënten populaties 
waarover normaliter weinig gerapporteerd wordt in literatuur. 
Hoofdstuk 6 vergelijkt postoperatieve morbiditeit en mortaliteit 
tussen open en laparoscopische resectie voor colorectaal carcinoom 
in gestratificeerde subgroepen patiënten, waaronder hoog-risico 
patiënten. Verschillende meta-analyses van RCT’s toonden een trend van 
lagere postoperatieve mortaliteit in het voordeel van de laparoscopische 
resectie, deze resultaten waren echter niet statistisch significant. 
Dit zou verklaard kunnen worden door de inclusie van relatief laag 
risicopatiënten en het gebrek aan statistische power. Deze studie toont 
een lagere postoperatieve mortaliteit na electieve laparoscopische 
resecties in vergelijking met een open resectie voor patiënten met 
niet lokaal uitgebreid en niet gemetastaseerd colorectaal carcinoom. 
Ook oudere kwetsbare patiënten (a priori hoog-risico patiënten) 
lijken te profiteren door verminderde cardiopulmonale complicaties. 
Deze bevindingen ondersteunen de wijdverspreide implementatie van 
laparoscopische chirurgie voor colorectaal carcinoom, ook voor hoog-
risico patiënten.
Laparoscopische chirurgie voor rectumcarcinoom is vlot en veilig 
geïmplementeerd in Nederland. Het percentage patiënten met een 
rectumcarcinoom dat in 2015 een laparoscopische resectie onderging 
is naar 83 procent gestegen. De postoperatieve resultaten van 
oudere gerandomiseerde studies, zoals de COLOR II trial, worden 
nog vaak geciteerd. Aangezien laparoscopische chirurgie een steile 
leercurve kent zou men zich kunnen afvragen of die data nog steeds 
representatief is voor de huidige nationale resultaten. Hoofdstuk 7 
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analyseert de huidige oncologische kwaliteit van laparoscopische 
resecties voor rectumcarcinoom in Nederland door middel van een 
gematchte vergelijking tussen de populatie van de DCRA en de COLOR 
II trial, met de CRM als primaire oncologische uitkomst. De studie 
toont de succesvolle implementatie van laparoscopische chirurgie voor 
rectumcarcinoom in Nederland met een significant lager percentage 
positieve CRM’s, een hoger gemiddeld aantal onderzochte lymfeklieren 
en lagere totale opnametijd. Het artikel geeft met behulp van audit 
data een accurate weergave van de huidige staat van de oncologische 
kwaliteit van resecties voor rectumcarcinoom. 
Hoofdstuk 8 toont de resultaten van patiënten met lokaal uitgebreid 
coloncarcinoom (LACC) in Nederland. De in opzet curatieve behandeling 
bestaat voor deze patiënten uit een volledige resectie van de tumor 
(R0 resectie) gevolgd door adjuvante systemische chemotherapie. Een 
niet radicale resectie heeft een negatieve prognostische impact op de 
lange termijn resultaten van deze patiënten. Behandeling van LACC is 
een nog onderbelicht gebied in de colorectale kankerzorg en is niet 
gecentraliseerd in expertcentra. Onze studie toont een lager percentage 
radicale resecties bij patiënten met LACC en een hoger risico op 
postoperatieve complicaties en mortaliteit in vergelijking met patiënten 
met minder vergevorderde dikke darmkanker. Deze resultaten tezamen 
met gegevens uit de literatuur suggereren ruimte voor verbetering 
van de behandeling van patiënten met LACC. Geoptimaliseerde 
preoperatieve beeldvorming, standaard multidisciplinair overleg, 
strategieën ter overbrugging in de spoedsetting tot aan de definitieve 
resectie, en verdere specialisatie en centralisatie van zorg zou de zorg 
voor deze patiënten kunnen verbeteren. Daarnaast kan op basis van 
huidige kennis en aanstaand onderzoek het gebruik van neoadjuvante 
behandelingsstrategieën geoptimaliseerd worden wat naar alle 
waarschijnlijkheid zal resulteren in minder irradicale resecties en 
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